

Index

Page references followed by b, f, or t denote boxes, figures, or tables respectively.

A

Abf1, 248, 252
Absent, small or homeotic (Ash), 199, 375, 495, 499, 502–503, 779
Accessibility hypothesis, 936–937, 938f
Acetylation. *See* Histone acetylation
Acetyl-CoA, 765–766, 765f–766f
Acetyl-CoA synthetase 1 (AceCS1), 765–766, 767f, 771
Acetylysine readers
 bromodomain (BrD) readers, 118–119, 130–136, 130f, 132f–133f, 135f
 DPF3b PHD fingers, 136
ACF (ATP-dependent chromatin assembly and remodeling factor), 567–568, 635
Actin-related proteins (ARPs), 562
Activation-induced deaminase (AID), 70
Activin, 725–726
Acute lymphoblastic leukemia (ALL), 749–751
Adaptive immune system, 739, 739f. *See also* Immunity
ADD domains, 207–209, 208f
ADE2 reporter gene, 243, 244f
Adrenoleukodystrophy (ALD), 833
AGAMOUS (AG), 470, 471f, 478
Aging, metabolism and, 778–781, 781f
AGO proteins, 379–381, 380f, 385–387, 385f
 in virus-induced gene silencing, 795–797, 795f, 797f
Agouti viable yellow allele
 environmental effects on, 416
 features of, 403f
 Momms influence on expression, 402–404
 parent-of-origin effects, 411–412, 412f
 transgenerational epigenetic inheritance at, 412–413, 413f
 variable expressivity, 411
 variegation, 402–404, 403f
AID (activation-induced deaminase), 70
ALAS1 (aminolevulinate synthase 1), 776
ALD (adrenoleukodystrophy), 833
ALL (acute lymphoblastic leukemia), 749–751
Allis, C. Davis, 317
 α -thalassemia X-linked mental retardation, 547–548, 845
ALT (alternative lengthening of telomeres)
 phenotype, 548
Alzheimer's disease, histone deacetylases (HDACs) and, 159
am gene, 300, 300f
Aminolevulinate synthase 1 (ALAS1), 776
AMP-kinase (AMPK), 96, 777
Angelman syndrome, 836–838, 836f, 837t, 838f
Ankyrin repeats, 209
ANRIL, 230, 479
Antennapedia complex (ANT-C), 491–492
Antisilencing, preventing heritable repression by, 476
Antisilencing function 1 (Asf1), 378, 581–584, 583f
Antp (*Antennapedia*), 491
APC tumor suppressor, 875
Aquifex aeolicus, histone deacetylase-like protein (HDLP) in, 149, 149f

Arabidopsis. *See also* Plants
AGO proteins, 379, 381
chromatin assembly factors, 378
components of epigenetic regulation, 369t–372t
demethylation, 373–374
HAG1, 375
heterochromatin organization, 451f
histone methylation, 375
METHYL-C-BINDING DOMAIN (MBD) proteins, 374
as model system, 51f, 52, 363–365, 368
Polycomb-group (PcG) proteins, 376–377, 466–467, 466f, 468t, 469, 469f, 471f, 474, 479–481, 479f
RNA interference (RNAi), 456–458, 457f
RNA polymerases, 385
S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE, 374
SWI2/SNF2 family, 377–378
vernalization, 789–793, 790f–791f, 793f–794f
ARABIDOPSIS TRITHORAX 1 (ATX1), 375
Aravind, L., 25
ARC (Argonaute chaperone) complex, 452, 453f
Arc enhancer, 23
Archaeal histones, 531–532, 532f
Arginine citrullination, 905
Arginine marks, readout of
 methylarginine marks by Tudor modules, 209–211, 210f
 canonical Tudor domains, 209–210, 210f
 expanded Tudor domains, 210–211, 210f
 unmodified arginine, 212–213, 213f
 chromodomains, 213, 213f
 PHD fingers, 212–213, 213f
 WD40 motifs, 212
Arginine methylation, 195–196. *See also* Protein arginine (R) methyltransferases (PRMTs)
Argonaute chaperone (ARC) complex, 452, 453f
Argonaute proteins, 447–449, 447f
 in *Arabidopsis*, 457
 in *Paramecium*, 326–327
ARKS, 758
ARPs (actin-related proteins), 562
ARTK, 758
ASE (autosomal signal element), 602
Asf1 (antisilencing function 1), 378, 581–584, 583f
Ash (Absent, small or homeotic), 199, 375, 495, 499, 502–503, 779
Asm-1 (*Ascospore maturation-1*), 305–307, 306f
ATAD2, 134–135
ATPase
 ISWI, 558–560, 559f, 562–563, 562f, 567–569
 nucleosome remodeling, 559–570, 559f, 561f–564f
 in plants, 377–378
ATP-citrate lyase, 765–766, 771
ATP-dependent chromatin assembly and remodeling factor (ACF), 567–568, 635
ATP-dependent chromatin remodeling, 437, 495–498, 496f

ATRX gene/protein, 41f, 42, 207–209, 208f, 437, 539, 539f, 547–548, 845
ATR-X syndrome, 207, 209
ATX1 (ARABIDOPSIS TRITHORAX 1), 375
Aubergine, 72
Aurora kinase, 57
Autoacetylation, 125–127, 127f
Autogamy, 315, 322
Autosomal signal element (ASE), 602
Axin fused (*Axin^{fu}*), 411, 413, 416

B

BAFs (BRG/BRM-associated factors), 563, 564f, 570, 722
BAH domains, readout of Kme marks by, 197, 199–202, 200f
BAPs (brahma-associated proteins), 563, 564f
Barker hypothesis, 852
Barr body, 87, 88f, 646
BASIC PENTACYSTEINE (BCP), 478
Baz1b, 95, 402
B-cell receptor (BCR), 740, 742–743
B cells
 conversion of mature B cells into functional T cells, 742
 development
 commitment, 740–741, 740f
 plasticity, 741–742, 741f
 schematic diagram, 739f
 malignancies, 749–751, 749f
 V(D)J recombination, 742–749
BCL9, 209
Beckwith–Wiedemann syndrome, 837t, 839–840, 840f
 β -globin loci
 human, 590
 mouse, 519–520, 520f
BET (bromodomain and extraterminal domain) proteins, 93, 131–132, 134, 136, 901–902
 inhibitors, 33–35, 34f, 36–38, 38f
bFGF, 725–726
BHC80, 211–212, 211f
Biparental hydatidiform mole (BiHM), 842–843
Bird, Adrian, 24
Bisphenol A (BPA), 768
Bisulfite sequencing, for mapping DNA methylation, 429b, 439
bithorax, 477
Blastocyst, 688, 689f–690f, 690–691, 697, 697f, 701–702, 713, 715
BLIMP1, 693f, 694–695, 696f
BMAL1, 773, 774f–775f, 775–778, 778f
Bmi1 gene/protein, 480–483, 910
BMP, 724
BMP4, 692, 693f
BMP8b, 692
BPA (bisphenol A), 768
BPTF, 198, 199f, 214–215, 214f, 217, 219
Brachyury, 694
Brahma-associated proteins (BAPs), 563, 564f

Index

- brahma (brm) gene/protein*, 495–498, 496f–497f, 558, 563, 570
BRCA1/2, epimutations in, 841
BRD2/3/4, 131–132, 132f, 134, 901
BRD3, 901
BRD4, 757, 757f, 901–902
 inhibition of, 33–34, 34f
BRD7, 901
BRDT, 34, 130f, 131, 901
Brg1 (brahma related gene 1), 407, 407f, 496, 503, 524, 563, 570
Bromodomain and extraterminal domain (BET)
 proteins, 93, 131–132, 134, 136, 901–902
 inhibitors, 33–35, 34f, 36–38, 38f
Bromodomain (BrD) readers, 118–119, 130–136, 130f, 132f–133f, 135f
 association with other chromatin modules, 132–134, 133f
 functions in gene expression, 134–135
 human proteins, 131–132, 132f, 134–135
 pharmacological inhibition in gene transcription, 135–136, 135f
 structure, 130–131, 130f
BRUSHY (BRU), 378
BRWD1, 134
Budding yeast. *See Saccharomyces cerevisiae*
- C**
Caenorhabditis elegans
 anatomy, 601f
 dosage compensation, 88, 599–616, 603f
 dosage compensation complex (DCC), 88, 600, 602–609, 605f–607f, 609f
 germ cell specification, 695
 hermaphrodites, 601–603, 601f, 603f, 615f
 as model system, 51f, 53
 Polycomb-group (PcG) proteins in, 466–467, 466f, 468t, 469f
 RNAi in, 53
 sex chromosome imbalance, 601
 X:A ratio, 601–602, 609
 X chromosome regulation, 599–616
 in germline development, 609–611, 610f
 global repression, 609–611
 meiotic silencing in males, 611–612
 MES histone modifiers and, 612–614, 613f
 overview, 600, 603f
 paternal X inactivation in embryos, 614–616, 615f
 X-linked genes, compensatory up-regulation of, 609, 609f
 X-linked genes, down-regulation of, 605, 607–609, 607f
CAF-1. *See Chromatin assembly factor 1*
Calorie restriction, 780–781
cAMP response element binding (CREB)-binding protein (CBP), 21, 22f, 120t, 126–129, 841, 843, 899, 901, 930, 935
Cancer, 859–886
 aberrant transcriptional activation, 481
 biological basis of, 860t, 861–862, 862f
 cellular pathways disrupted in, 861t
 chromatin and, 862, 863t–864t, 864–865, 864f, 867f, 876–880
 chromosomal translocations and, 514–515
 DNA methylation, 424, 863t, 865–872, 865t, 866f–867t, 869t, 871t, 872f
 abnormalities as biomarkers, 881–882
 CpG islands, 866–870, 866f–867f, 873, 877–880, 879f
 hypermethylation, 866–872, 866f–867f, 869t, 871t
 hypomethylation, 865–866, 866f
 involvement of methylation machinery in tumorigenesis, 880–881
 mutation of 5mCs, 868
 reprogramming of methylation patterns, 879f
 technology used to identify methylation patterns, 870–871
 timeline for role elucidation, 865t
DNA methyltransferases (DNMTs) and, 865, 880–884
drug-discovery challenges for histone-modifying targets, 910–914, 911f, 913t
 approved epigenetic drugs, 910–912, 911f
 drug resistance, 910
 process of drug-discovery, 912, 914
epigenetic therapy, 90–93, 91f–92f
genetic mutations of epigenetic modifiers in cancer, 861t
histone H3 mutations in pediatric brain tumors, 40–42, 41f
histone modifications, 159, 863t, 874, 877–881, 879f, 895–919
 acetylation, 898–902
 arginine citrullination, 905
 atypical, 905–906
 cross talk, 906–910, 907f
 DNA damage repair and, 908, 909f, 910
 drug-discovery challenges for histone-modifying targets, 910–914, 911f, 913t
 HAT deacetylases, 916t–917t
 HAT mutations, 915t
 histone demethylases, 918t–919t
 histone methyltransferases, 917t–918t
 lysine ADP-ribosylation, 905–906
 methylation, 902–905, 902f
 N6-formylation, 906
 O-GlcNAcylation, 906
 overview, 896–897, 897f
 histone variants and, 548
isocitrate dehydrogenase (IDH) mutations, 868, 873–874
loss of imprinting (LOI), 873
lymphoid, 749–751, 749f
molecular anatomy of silenced cancer genes, 876–881
mutations and, 94f, 861, 861t, 862f, 863t–864t, 864–865, 868
overview, 860
pancreatic neuroendocrine tumors (PanNETs), 548
research in understanding gene silencing in, 877t, 881
therapy, 882–886, 883f
 bromodomain and extraterminal domain inhibitors, 33–35, 34f
 combination therapy, 885–886
 DNMT inhibitors, 882–884, 883f
 drug development, 884–885
 HDAC inhibitors, 883f, 884
 tumor progression, 872–876, 872f, 874f
 “two- or multiple-hit” hypothesis, 861
Cas, 932
CBP. *See cAMP response element binding (CREB)-binding protein*
CD4⁺ cells, 739, 739f
CD8⁺ cells, 739, 739f
C/EBP α , 720
CEH-39, 602
Cell cycle, histone variant deposition throughout, 534
Cell fates
 changed by lineage-associated transcription factors, 715–716
 reprogramming, 88–90, 89f (*see also* Reprogramming)
Cell proliferation, control by PRC2, 481–482, 482f
Cell therapy, 729–730, 729f
Cellular memory concept, 102, 465, 465f, 491, 491f
cenH, 452
CenH3 (centromeric-specific H3), 535, 535f, 537, 584
CENP-A, 61, 61f, 68, 270, 274f, 280–281, 280f, 282f, 283–284, 284f, 287f, 535, 547, 589
cen RNAs, 452
Central dogma, 50
Centromeres
 function of, 68
 histone H3 variant at, 534–535, 535f, 537
Schizosaccharomyces pombe, 270, 274–284
 abnormal structure from defective heterochromatin, 284f
 epigenetic inheritance of functional centromere state, 281, 283
 silent chromatin at *cenH* regions, 285
 sister-centromere cohesion, 283–284
CFP1 (CxxC finger protein 1), 30–32, 31f
CGG repeat, in fragile-X syndrome, 848, 849f
Chalcone synthase (*CHS*) gene, 365, 373f
Chaperones
 chromatin assembly factors in plants, 378
 histone, 567, 579, 582–584, 583f
CHARGE syndrome, 497–498
CHARM DNA methylation analysis, 429b
CHD1, 204, 205f, 219, 566, 568, 722
CHD7 gene, 497–498, 502
Chfr epigenetic silencing, 875
ChIA-PET (chromatin interaction analysis with paired-end tag sequencing), 517, 519
Chimera formation, 714t
ChIP loop assay, 519
Chp1, 275, 452, 457
Chp2, 453
CHRAC (chromatin accessibility complex), 635
Chromatin, 48, 54–55
 advances in understanding, 929–930
 assembly and histone modifications, 581–582, 582f
 ATP-dependent chromatin remodeling, 437, 495–498, 496f
 bivalent, 79–81, 81f
 boundaries in *Schizosaccharomyces pombe*, 277, 279–280, 279f
 cancer and, 862, 863t–864t, 864–865, 864f, 867f, 876–880
 chromosome folding and epigenetic state, 44–46, 45f
 in ciliates, 315–318
 differentiation and nucleosomes histone marks, 930
 DNA *versus*, 55f
 duplication of, 579, 580f
 facultative, 87–88
 H3 amino-terminal tail role in higher-order chromatin structures, 257
 heterochromatic repression, 249, 251–252, 251f
 histone variants and
 chromatin location, 543–544
 chromatin properties, affect on, 544–545
 chromatin regulation, roles in, 542–543
 H3.3 at active chromatin, 537–539, 538f–539f
 X inactivation, 546, 546f
 history of epigenetics research, 4–7
 in human disease, 833, 841–851, 842t, 847t, 849f
 inflammatory response, chromatin-mediated control of, 751–754, 753f
 lncRNAs (long noncoding RNAs), 18–20
 long-range interactions, 507–525
 analysis of, 515–519

- ChIA-PET assay, 517f, 519
- ChIP loop assay, 519
- chromosome conformation capture (3C), 516, 517f, 518
- 5C technology, 518–519
- 4C technology, 518
- overview, 515–516
- genome folding, cellular heterogeneity in, 519
- interchromosomal, 508, 521–522, 522f
- looping interactions, 519–524
 - associations between groups of active and inactive loci, 522–523
 - building chromatin loops, 524
 - CTCF role in, 524
 - gene regulation and, 524
 - between genes and regulatory elements, 519
 - interchromosomal interactions, 521–522, 522f
 - at mouse globin loci, 519–520, 519f
 - between regulatory elements, 520–521
 - topologically associating domains (TADs), 523
- nuclear architecture and, 510–514
 - chromosomal translocations, 514–515, 515f
 - nonrandom genome organization in nucleus, 510
 - nuclear periphery, physical interaction with, 510–512, 511f
 - spatial gene clustering, 512–514, 514f
- overview, 508
- spatial gene clustering, 512–514, 514f
- nucleolus, 512–513
- transcription factories, 513–514, 514f
- tRNA, 513
- metabolic signaling to, 763–782
- modification, 62–66
 - combinatorial readout of, 63, 64f, 65
 - coordinated, 62f
 - domain extension by KMT complexes, 65f
 - dosage compensation and, 632–633
 - enzymology of, 657
 - RNAi-mediated in animals, 458–459
 - RNAi-mediated in *Arabidopsis*, 456–458, 457f
 - in spermatogenesis, 698
 - X inactivation in mammals, 647, 656–657
- modifying activity of Polycomb repressive complex 2 (PRC2), 470, 472–473
- nuclear localization, 932–933
- nucleosome remodeling, 566–568
- organization, higher-order, 66–69, 67f
- as response to DNA concentration in nucleus, 934
- RNAi-mediated modifications
 - in animals, 458–459
 - in *Arabidopsis*, 456–458, 457f
- scanning, 930–931
- in *Schizosaccharomyces pombe*, 269–289
- secondary functions of Sir proteins and silent chromatin, 261–264, 263f
- silencing marks, 467–476
- silent in *Schizosaccharomyces pombe*, 285–286
 - cenH* regions, 285
 - facultative heterochromatin, 285–286
 - mating-type loci, 285
 - telomeres, 285
- structure (see Chromatin structure)
- template alteration, 59–60, 59f
 - cis* effects, 59, 59f
 - histone exchange, 59f, 60
 - trans* effects, 59f, 60
- therapeutic modalities based on, 231–232
- transcriptional memory, 937f
- trans*-interaction of telomeres and perinuclear attachment of heterochromatin, 257–258, 258f–259f
- weak binding interactions, 930–931
- ZF-CxxC protein recruitment, 30–32, 31f
- Chromatin accessibility complex (CHRAC), 559, 559f, 635
- Chromatin assembly factor 1 (CAF-1), 61, 378, 533, 534f, 581–584, 583f, 586, 700
- Chromatin assembly factors, in plants, 378
- Chromatin immunoprecipitation (ChIP)
 - chromatin modifications in X inactivation, 657
 - histone mark characterization, 195
 - MSL binding on X chromosome, analysis of, 628–631, 629f
- Chromatin remodelers, 59–60, 59f, 579
 - cis* effects, 59, 59f
 - histone modification recognition by, 568
 - histone variants and, 569–570
 - transcription regulation and, 563–566
 - trans* effects, 59f, 60
- Chromatin-remodeling complex
 - dosage compensation in *Drosophila*, 625–627
 - in plants, 377–378
- Chromatin structure
 - in *cis*, human disease related to, 847–851, 847t, 849f
 - in facioscapulohumeral dystrophy (FSHD), 849f, 850–851
 - fragile-X syndrome, 847t, 848–850, 848f–849f
 - thalassemias, 847–848
 - higher-order on inactive X chromosome, 657–658
 - inheritance of, 579–589
 - microscopic, 67
 - olfactory receptor (OR) clusters, 822, 823f
 - in *trans*, human disease related to, 841–847, 842t
 - α -thalassemia X-linked mental retardation, 845
 - ICF (immunodeficiency, centromeric region instability, and facial anomalies) syndrome, 845–846
 - Kabuki syndrome, 846–847
 - recurrent hydatidiform mole, 842–843
 - Rett syndrome, 843–845, 844f
 - Rubinstein–Taybi syndrome, 843
 - Schimke immuno-osseous dysplasia (SIOD), 846
- Chromatoid body, 698
- Chromodomains
 - readout of methyllysine marks by single, 202–203, 202f
 - readout of methyllysine marks by tandem, 204, 205f
- CHROMOMETHYLASE 2 (CMT2), 372
- CHROMOMETHYLASE 3 (CMT3), 200–202, 200f, 231, 372, 457–458
- Chromosome conformation capture (3C), 243
 - ChIA-PET assay, 517f, 519
 - ChIP loop assay, 519
 - comprehensive analysis of parts of 3C libraries, 518
 - 5C technology, 518–519, 523
 - 4C technology, 518
 - genome folding heterogeneity revealed by, 519
 - global analysis of complete 3C libraries, 518
 - Hi-C analysis, 46, 523
 - overview of, 516, 517f
- Chromosome fragmentation, in ciliates, 321
- Chromosomes
 - chromatin (see Chromatin)
 - folding, 44–46, 45f
 - formation, 68
 - instability and DNA hypomethylation, 438
 - looping interactions, 519–524
 - nonrandom genome organization in nucleus, 510
 - polytene, 345–346, 497f, 538f, 566, 635
 - territories and genes in three-dimensional space, 509–510, 509f
 - translocations, 514–515, 515f
- Chromosome segregation, in *Schizosaccharomyces pombe*, 283–284
- Chronic obstructive pulmonary disease (COPD), 160
- CHS* (chalcone synthase) gene, 365, 373f
- Cid12, 454–455
- Ciliates, 313–333
 - active *versus* silent chromatin in, 315–318
 - biological roles of programmed genome rearrangements, 330–332
 - chromatin modifications, 317–318, 317f
 - conjugation, 315
 - DNA elimination, 319–321
 - biological roles of, 330–332
 - as DNA splicing mechanism, 331–332
 - as genome defense mechanism, 331
 - guided by homology-dependent mechanisms, 322–325
 - guided by small RNA-directed trans-nuclear comparison of whole genomes, 325–328
 - involvement of parental macronuclear transcripts in, 327–328
 - transposases and, 321–322
 - DNA unscrambling, 321, 329–330, 329f–330f
 - as DNA splicing mechanism, 331–332
 - templated by maternal RNAs, 329–330
 - gene expression compartmentalization, 314
 - genome-wide rearrangements, 319–322, 320f
 - chromosome fragmentation, 321
 - DNA elimination, 319–321
 - DNA unscrambling, 321
 - transposases, 321–322
 - histone modifications, 317–318, 317f
 - histone variants, 316–317
 - homology-dependent gene silencing, 318–319
 - silencing induced by dsRNA, 319
 - transgene-inducing silencing, 318–319
 - life cycle and fate of nuclei, 316f
 - macronucleus
 - chromosome fragmentation, 321
 - described, 313–314
 - division, 314
 - histone variants, 316–317, 317f
 - mating-type, epigenetic regulation of, 332, 332f
 - micronucleus
 - described, 313–314
 - division, 314
 - histone variants, 316–317, 317f
 - spontaneous elimination of foreign sequences introduced in micronuclear genome, 325
 - as model systems for studying epigenetics, 51f, 52
 - overview, 314
 - RNA interference (RNAi), 72, 314
 - scnRNA-induced heterochromatin formation preceding DNA excision, 328
 - short RNAs, 314
- CIMP (CpG island methylator phenotype), 873–875
- Circadian clock, 772–778, 774f–775f
- Citrullination, 905
- CLAMP, 630
- CLOCK, 97, 773–778, 774f–775f, 778f
- Cloning of animals, 713–714
- CLP (common lymphoid progenitor), 739, 739f
- Clr3, 453–454
- Clr4, 450, 452, 454–456
- CMT2, 372
- CMT3, 200–202, 200f, 231, 372, 457–458
- c-Myc, 722
- Cofactors, of histone acetyltransferases (HATs), 126

Index

- Cohesin, 263, 283–284
 chromosome looping and, 524, 524f
 control of ordered V(D)J recombination, 748–749
 in plants, 376
 protocadherin (Pcdh) expression and, 817–818
 trithorax group (TrxG) proteins and, 501
- COLDAIR*, 479, 792, 793f
- Common lymphoid progenitor (CLP), 739, 739f
- COMPASS, 499, 608
- Complete hydatidiform mole, 842–843
- Condensin complex, 603, 605f
- Conjugation, in ciliates, 315
- COOLAIR*, 479, 792, 793f
- COPD (chronic obstructive pulmonary disease), 160
- CoRest corepressor complex, 58
- Cosuppression, 365
- CpG dinucleotides
 in cancer, 862, 866
 H3K4 methylation linked to unmethylated, 182, 183f
 JHDM1 binding to CpG DNA, 183
 methylation, 69, 862, 866 (see also DNA methylation)
 in mammals, 424–425
 sites, 196–197
 in plants, 368
- CpG island methylator phenotype (CIMP), 873–875
- CpG islands
 in cancer, 866–870, 866f–867f, 873, 877–882, 879f
 histone variants and, 547–548
 in mammals, 428–429, 430f
 methylation, 69, 866–870, 866f–867f, 873, 877–882, 879f (see also DNA methylation)
 of promoter, 438
 protection from, 577
 X inactivation and, 657, 658–659
 in plants, 368
 promoters, 32, 577
 ZF-CxxC protein recruitment, 30–32, 31f
- cpSRP43, 213, 213f
- CpXpG trinucleotide, 577
- CREBBP, 749–750
- CRISPR, 932
- Cross talk between histone marks, 219–220
 in cancer, 906–910, 907f
 cis cross talk, 908
 DNA damage repair, 908–910, 909f
 lysine and arginine methylation, 907–908, 907f
 Kme-Kac cross talk, 220
 Kme-Kub cross talk, 220
 Kme-Rme cross talk, 220
 Kme-Sph cross talk, 219
- Croziers, 297, 298f
- CRY, 773, 774f, 777
- Csflr*, 740
- CTCF
 Beckwith–Wiedemann syndrome and, 839, 840f
 control of ordered V(D)J recombination, 748–749
 poly(AD-ribose) polymerases (PARPs), 770
 protocadherin (Pcdh) expression and, 817–818
 role in looping and chromosome organization, 524
- CURLY LEAF (CLF), 467, 470, 478, 791
curly whiskers, 408, 417
- CxxC finger protein 1 (CFP1), 30–32, 31f
- Cyclin-dependent kinase, 57
- Cyp33, 218, 218f
- Cystic fibrosis, 834–835
- Cytosine
 demethylation in plants, 373–374
 methylation, 196–197, 425, 425f (see also DNA methylation)
 novel modifications of, 24–26, 25f
 in zygotes and preimplantation embryos, 432
- DNA glycosylases in plants, 373–374
- DNA methylation, 178–181
 in cancer, 424, 863f, 865–872, 865t, 866f, 867f, 869t, 871t, 872f
 abnormalities as biomarkers, 881–882
 CpG islands, 866–870, 866f–867f, 873, 877–880, 879f
 hypermethylation, 91, 866–872, 866f–867f, 869t, 871t
 hypomethylation, 90–91, 865–866, 866f
 involvement of methylation machinery
 in tumorigenesis, 880–881
 mutation of 5mCs, 868
 reprogramming of methylation patterns, 879f
 technology used to identify methylation patterns, 870–871
 timeline for role elucidation, 865t
 chromatin remodeler interaction with, 569
 during development, 578f, 699–701, 703
 in embryonic stem cells, 24–26, 26f
 fully methylated 5mCpG, 221–223, 222f
 methylcytosine-binding (MBD) proteins, 222–223, 222f
 methylcytosine-binding Zn-finger proteins, 223
 future directions, 439–440
 genetic and environmental factors that induce epigenetic changes, 439
 modulation of epigenetic state, 440
 modulation of reversible epigenetic states, 440
 profiling epigenome in disease, 439
 reprogramming by Tet-mediated 5mC oxidation, 440
 genomic imprinting and, 678–680
 germ cell, 696–697
 hemimethylated 5mCpG, 223–226, 224f–225f
 mammalian SRA domains, 223–225, 224f–225f
 plant SRA domains, 225–226
 histone methylation linked to, 183–184, 231, 301–302, 436–437
 history of epigenetics research, 4
 in human disease, 197, 833
 interplay with histone modification, 181–185, 183f, 185f–186f
 H3K4 methylation, 436–437
 H3K9 methylation, 436
 H3K27 methylation, 437
 histone deacetylation, 436
 in mammals, 434, 436–437
 maintenance methylation, 178, 179f, 299, 300–301, 425–428, 426f
 maintenance of patterns, 577–579
 in mammals, 423–440
 as cell memory system, 425
 CpG islands, 428–429, 430f
 demethylation, 429–432
 de novo methylation, 425–428, 426f
 diseases and, 437–439
 DNA methyltransferase functions, 427t
 establishment of patterns, 425–429, 427f
 future directions, 439–440
 gene expression regulation by, 433–434
 interplay with histone modification, 434, 436–437
 mapping methylation, 429b
 overview, 424
 in neurogenesis, 809–811
 in *Neurospora crassa*, 69, 298–304
 components of methylation machine, 302f
 histone involvement in, 301–302
 maintenance methylation, 299, 300–301
 modulators of, 302, 304
 overview, 298–299
- D
D4ZA, 849f, 850
D4ZA-binding element (DRE), 849f, 850
DamID, 288, 351
dam methylase, 251
Dax1, 722
Daxx, 41f, 42, 548
DBE-T, 849f, 850–851
DCC. See Dosage compensation complex
DCLI gene, 326
DECREASE IN DNA METHYLATION 1 (DDM1), 377, 457
DEFECTIVE IN MERISTEM SILENCING3/ INVOLVED IN DE NOVO (DMS3/ IDN1), 376
δβ-thalassemias, 847–848
DEMETER (DME), 373–374
DEMETER-LIKE proteins (DML2/3), 373–374
Demethylation
 during development, 429–431, 579
 in germ cells, 696
 in plants, 373–374, 375
Development
 demethylation during, 429–431, 579
 DNA methylation, 578f, 699–701
 epigenetic reprogramming cycle in mammalian, 690
 fertilization, epigenetic events ant, 699–700
 gametogenesis, 698–699
 germline and pluripotent stem cells, 687–705
 imprint acquisition and erasure in development, 672f
 maternal inheritance, 699
 Mommies importance in, 400–402
 nucleosome remodeling in, 570
 patterning, mobile small RNAs and, 28
 plant, unique aspects of, 366–368, 367f
 X inactivation in mammals, developmental regulation of, 646–647
 zygote to blastocyst, 701
Developmental noise, 416–417
DFR (dihydroflavonol reductase) gene, 373f
Dicer, 72
 small RNA biogenesis, 447–448, 448f, 796
DICER-LIKE (DCL) 1 through 4, 28, 379, 380f, 381, 385, 385f, 387, 456–458, 457f, 795–796, 796f
Diet and epigenotypes in aging and disease, 851–852
Diffuse large B-cell lymphoma, 749–750
dim-5 gene, 301–302, 304
Diseases. See also Human disease; *specific diseases*
 DNA methylation in mammals and, 437–439
 chromosome instability and DNA hypomethylation, 438
 methylation of promoter CpG islands, 438
 methyl CpG as hot spots for mutation, 437–438
 profiling epigenome in disease, 439
 Rett syndrome, 438–439
 induced pluripotent stem cells (iPSCs), research applications for, 726–730
Dlk1, 673, 675–679
Dlx2, 811
DMM (DNA methylation modulator), 302, 304
DMR (differentially methylated region), 675–679, 675t, 676f
DNA
 central dogma and, 50
 chromatin *versus*, 55f
 difficulty of reading genomic, 933–934
 double-strand break repair, 541
 DNA damage binding 1 (Ddb1), 456
 DNA damage repair in cancer, 908, 909f, 910
 DNA demethylation in mammals, 429–432
 active and passive during development, 429–431
 Tet-mediated, 431–432, 431f, 440

- overview, 69–71, 70f
- pattern generation during development, 578f
- in plants, 577–578
 - DNA methyltransferases, 372
 - RNA-directed DNA methylation, 384–387, 385f
- postimplantation changes, 578–579
- resetting patterns during cellular reprogramming, 721–722
- X inactivation and, 657–659
- DNA methylation modulator (DMM), 302, 304
- DNA methyltransferases (DNMTs)
 - in cancer, 865, 880–884
 - de novo, discovery of, 426, 428
 - Dnmt1, 69, 178, 179f, 231, 425–428, 426f, 427t, 428f
 - ATP-citrate lyase and, 766
 - BAH domains, 201
 - preference for hemimethylated sites, 223, 577
 - tethering to chromatin, 219
 - Dnmt2, 428, 428f
 - Dnmt3 family, 69, 178, 180–182, 180f, 203, 212, 426f, 427t, 428, 428f, 696
 - in neurogenesis, 809–811, 809f
 - ICF (immunodeficiency, centromeric region instability, and facial anomalies) syndrome and, 846
 - inhibitors, 882–884, 883f
 - maintenance, 178, 179f, 425–428, 426f
 - overview, 69
 - in plants, 372
 - SAM and, 767, 767f
 - structure of mammalian, 428f
- DNA modification, in plants, 368, 369t, 456–458, 457f
- DNA packaging
 - challenge of storing DNA in vivo, 509–510
 - histone variants and, 531, 547
- DNA replication
 - bulk histone deposition after, 533–534, 534f
 - histones dynamics during, 582–589
 - nucleosome disruption during, 577, 579, 585
- DNase I-hypersensitive sites, 557–558, 557f, 741
- DNase I-hypersensitivity analysis, 557, 557f
- DNA translocases, 560
- DNMTs. *See* DNA methyltransferases
- DOMAINS-REARRANGED METHYLTRANSFERASES (*DRM*), 372, 456, 614, 797–798
- Dosage compensation
 - in *Caenorhabditis elegans*, 88, 599–616, 603f
 - in *Drosophila*, 88, 621–636
 - chromatin modifications, 632–633
 - chromatin-remodeling complex assembly, 625–627
 - discovery of, 623–624, 623f
 - evolution of, 635–636
 - global chromatin factor influence on male X chromosome, 635
 - model for mechanism of, 633–634
 - MSL binding on X chromosome, analysis of, 628–631, 629f–630f
 - MSL complex assembly and targeting on X chromosome, 627–628, 628f
 - nuclear organization, 634–635, 634f
 - overview, 622
 - regulators of, 624–625
 - roX RNAs and, 627–628, 628f
 - transition from initiation sites to target genes, 631–632, 631f–632f
 - in mammals, 641–662
 - overview, 642
 - sex determination and, 643–644, 643f
 - X inactivation, 646–660
 - X-linked genes, up-regulation of, 644–645, 646f
 - X reactivation and reprogramming, 660–662
 - overview, 88
 - Dosage compensation complex (DCC), 88, 600, 602–609, 605f–607f, 609f
 - components of, 603–604, 604t
 - condensin complex, resemblance to, 603, 605f
 - down-regulation of X-linked genes, 605, 607–609, 607f
 - effects of, 605, 607–609, 607f
 - her-1* repression, 608–609
 - overview, 600, 603f
 - recruitment and spreading of, 604–605, 606f
 - Dot1, 15, 256, 614
 - Dot1L, 15, 751
 - Dot1p, 171–173, 173f
 - doublesex* (*dsx*), 624
 - Double-strand break repair, 541
 - Double-strand breaks, introducing, 726
 - Double-stranded RNA (dsRNA). *See also* RNA interference (RNAi)
 - silencing in ciliates, 319
 - synthesis and siRNA generation, 454–455
 - DPY-21, 608
 - DRE (D4Z4-binding element), 849f, 850
 - Drosophila*, 337–358
 - chromatin annotation of genome, 352f
 - chromosomal proteins
 - complexes to maintain and spread heterochromatin structure, 348–351
 - distribution and association patterns, 345–346
 - identified by screens for suppressors and enhancers of PEV, 342–345, 344f
 - modifiers of, 342–345, 344f
 - dosage compensation, 88, 621–636
 - chromatin modifications, 632–633
 - chromatin-remodeling complex assembly, 625–627
 - discovery of, 623–624, 623f
 - evolution of, 635–636
 - global chromatin factor influence on male X chromosome, 635
 - model for mechanism of, 633–634
 - MSL binding on X chromosome, analysis of, 628–631, 629f–630f
 - MSL complex assembly and targeting on X chromosome, 627–628, 628f
 - nuclear organization, 634–635, 634f
 - overview, 622
 - regulators of, 624–625
 - roX RNAs and, 627–628, 628f
 - transition from initiation sites to target genes, 631–632, 631f–632f
 - E(var)*, 339, 341t, 342–343, 348
 - germ cell specification, 695
 - heterochromatin, 337–358
 - packaged into nucleosome array, 342f
 - silencing, 346–348
 - spatial organization, 351–354, 354f
 - spreading, 348–351, 349f–350f
 - targeting of formation, 354–356
 - histone modifications, 346–348, 347f
 - maternal inheritance, 699
 - as model system, 51f, 52–53
 - neurons, 813
 - Polycomb-group (PcG) proteins, 466–468, 466f, 468t, 469f, 470, 473–478, 477f, 480, 483
 - polytene chromosomes, 345–346, 497f, 538f, 566, 635
 - position effect variegation (PEV), 337–345, 340f, 348, 349f, 353, 356, 357
 - screens for suppressors and enhancers of, 342–345
 - sex determination, 625f
 - silencing in, 72, 346–348
 - Su(var)*, 339, 340f, 341t, 342–348, 347f, 350–351, 350f, 354f, 357
 - transposable elements, 341–342, 342f, 345, 355–356
 - trithorax group (TrxG) in, 491f–493f, 492–494, 494t, 496–499, 496f–497f, 501–504
 - variegating phenotype, 339, 340f, 341–342
 - white* mutation, 339, 340f, 341, 342f, 343, 345, 349, 349f, 352–353, 355
 - X:A ratio, 624, 625f
 - Dscams, 813
 - dsRNA. *See* Double-stranded RNA
 - E**
 - E(var)*, 339, 341t, 342–343, 348
 - E3 SUMO ligase, 217–218
 - E-cadherin*, 720
 - EKLF1, 523–524
 - Elf5*, 703
 - Ema 1p*, 327–328
 - Embryonal carcinoma (EC) cells, 714
 - Embryonic ectoderm development (Eed)* gene, 408, 409
 - EMBRYONIC FLOWER2 (EMF2), 467, 469–470, 471f, 478
 - Embryonic stem cells
 - cytosine modifications in, 24–26, 26f
 - derivation of, 702–703, 702f, 714–715
 - epigenetic properties of, 703–704
 - genetic modification of, 726, 727f
 - germ cell development from, 697–698
 - induced pluripotent stem cells (iPSCs) equivalency to, 730
 - overview, 688
 - pluripotent state maintenance by transcription factors, 722, 723f
 - reprogramming capacity of, 704
 - X inactivation state in, 724
 - Emx2*, 822
 - ENCODE project, 871
 - Enhancement of position effect (*Epe1*), 279–280, 279f
 - Enhancer of Zeste, 495
 - Enhancer RNAs (eRNAs), 21–23, 22f
 - ENU. *See* Ethylnitrosourea (ENU) mutagenesis
 - Environment
 - epigenetic regulation in plant response to, 787–803
 - epigenetic response to, 96–98, 97f
 - interplay of epigenetic mechanisms and, 931–932
 - metastable epialleles, effects on, 416, 416f
 - ncRNAs function in response to environmental stimuli, 98
 - Environmental and epigenetic interactions in human disease, 851–852, 851f
 - diet and epigenotypes in aging and disease, 851–852
 - fetal or infant experiences and epigenotypes, 852
 - Enzymes, chromatin regulation and, 768–770
 - EP300, 749–750, 899, 901, 915t
 - Epe1* (enhancement of position effect), 279–280, 279f
 - Epiblast stem cells (EpiSCs), 724–726
 - Epigenetic control, 101–103, 103f
 - Epigenetic inheritance, 98–101, 100f
 - Epigenetic memory, 722, 801
 - Epigenetic research, big questions in, 103–105, 104f
 - Epigenetics, 48
 - defining, 2, 54
 - genetics *versus*, 49–51, 54f
 - model systems for studying, 51–53, 51f
 - origin of, 50
 - phenotype examples, 49f

Index

- Epigenetic therapy, 90–93, 91f–92f
Epigenome, 566
 cancer, 861
 circadian, 772–778
 spatial organization of, 45f
Epigenomic reference maps, 78–81, 78f–79f, 81f
Epimutations, in human disease, 835–841
ERK, 703
eRNAs. *See* Enhancer RNAs
Esrrb, 724
Ethylnitrosourea (ENU) mutagenesis, 397, 406–409
 production of hypomorphic alleles, 406–408, 407f
 screen for genes involved in X inactivation choice, 408
 sensitized suppressor screen, 409
Euchromatin, 66
 defined, 242
 heterochromatin distinction from, 73–76, 74f, 76f
Euplotes, 320–321
Evolution of eukaryotic core histones from archaeal histones, 531–532, 532f
Extended gene concept, 81–83, 82f
EZH2, 750, 904, 910, 930
EZH2 inhibitors, 92
- F**
Facioscapulohumeral dystrophy (FSHD), 849f, 850–851
FACT complex, 60, 583f, 584
FAD (flavin adenine dinucleotide), 768
Fbxo15, 716–717, 720
female-sterile homeotic (fsh), 492, 501
Fertilization, epigenetic events ant, 699–700
FERTILIZATION-INDEPENDENT ENDOSPERM (FIE), 469–470, 791
FERTILIZATION-INDEPENDENT SEEDS 2 (FIS2), 377, 467, 478, 481
Ft3, 280
FISH. *See* Fluorescence in situ hybridization
Fission yeast. *See* *Schizosaccharomyces pombe*
5C technology, 518–519, 523
5-hydroxymethylcytosine (5hmC), 24–26, 26f
5-methylcytosine (5mC), 24–25, 26f, 69, 865, 867
 mutation of, 70, 868
 in plants, 368
 Tet-mediated oxidation, 70, 431–432, 440
FK228, 160–161, 161f
Flavin adenine dinucleotide (FAD), 768
FLOWERING LOCUS C (FLC), 470, 471f, 478–479, 788–793, 790f–791f, 793f–794f
FLOWERING LOCUS D, 470, 471f, 478–479
FLOWERING LOCUS T (FT), 470, 471f
Fluorescence in situ hybridization (FISH)
 long-range chromatin interactions, study of, 508, 510, 512–514, 521–522
 three-dimensional DNA (3D DNA-FISH), 745, 746–747
FMRI, 848–850, 849f
Fob1 (fork barrier protein 1), 263
Forkhead box protein 3a (Foxo3a), 406
4C technology, 518
fox-1 gene/protein, 601–602
FoxA, 498
Fragile-X syndrome, 834, 847t, 848–850, 848f–849f
fragilis, 692
FRIGIDA, 790, 792
fsh (female-sterile homeotic), 492, 501
FSHD (facioscapulohumeral dystrophy), 849f, 850–851
FTO gene, 764
Fusion hybrids, 715
FWA gene, 365, 387
- G**
G9a, 208f, 209, 221, 904
GAGA factor, 502
Gametes, transgenerational epigenetic inheritance via, 412–413, 413f–414f
Gametogenesis, 698–699
Gametophytes, 366, 367f
 $\gamma\delta\beta$ -thalassemias, 847–848
GATA1, 523–524
Gcn5, 120–122, 120t, 121f, 123f, 124–126, 128–129, 130f, 131–132, 565f, 568, 899
Gene concept, extended, 81–83, 82f
Gene expression
 dosage compensation complex (DCC) and, 605, 607–609, 607f
 lncRNAs (long noncoding RNAs) and, 18–20, 19f
 protocadherin (Pcdh), epigenetic control of, 814, 816f, 817–818
 regulation by DNA methylation in mammals, 433–434
 recruitment of methyl-CpG binding proteins and repressor complexes, 433–434
 transcription binding factor, interference with, 433
 regulation inflammatory by signal-induced RNA elongation, 755–757, 756f
 replication timing correlation to, 591–592
 variable expressivity, 410–411
Gene regulation
 looping interactions and, 524
 nuclear periphery role in, 510–512, 511f
Genes
 clock-controlled, 773–774, 775f, 776–778, 778f
 spatial gene clustering, 512–514, 514f
 nucleolus, 512–513
 transcription factories, 513–514, 514f
 tRNA, 513
Gene targeting, 726, 727f
Genetics, epigenetics *versus*, 49–51, 54f
Genome
 nonrandom genome organization in nucleus, 510
 organization and size, comparison of, 76, 77f
 size of human, 48
Genome defense system
 RIP (repeat-induced point mutation) in *Neurospora crassa*, 299–300, 299f–300f
 siRNA-mediated silencing in plants as, 382–384
Genomic imprinting, 667–684
 cis-acting silencing in imprinted gene clusters, 680–683, 681f
 defined, 668
 DNA methylation and, 678–680
 embryonic and neonatal growth control, 673
 epigenetic gene regulatory system, 671–673
 erasure of imprints in early germ cells, 698–699
 evolution, 673–674
 parental conflict hypothesis, 673–674
 trophoblast defense hypothesis, 674
 features of, 671b
 functions in mammals, 673–674, 674f
 future directions in, 683–684
 gene clusters, 674–677, 675t, 676f
 historical perspective, 669–671
 imprint acquisition and erasure in development, 672f
 imprint control elements (ICEs), 674–677, 675t, 676f
 key discoveries, 673–683
 as model for mammalian epigenetic regulation, 683
 mouse models to study, 669, 669f
 nuclear transfer experiments, 670, 670f
 overview, 668
 Xp inactivation, 614–616, 615f
Genomic imprinting disorders, 836–841, 837t
 Angelman syndrome, 836–838, 836f, 837t, 838f
 Beckwith–Wiedemann syndrome, 837t, 839–840, 840f
 Prader–Willi syndrome, 674, 836–839, 836f, 837t, 838f
 pseudohypoparathyroidism, 837t, 840–841, 840f
 Silver–Russell syndrome, 837t, 840
Germ cells, 687–705
 development from pluripotent embryonic stem cells, 697–698
 gametogenesis, 698–699
 genomic imprint erasure in early, 698–699
 in mammalian developmental cycle, 689–691
 overview, 688
 pluripotent cell lines from, 703
 specification, mechanisms regulating, 691–699
 Blimp1 role in, 694–695
 early germline development in mammals, 691–694, 692f–693f
 epigenetic programming regulation after specification, 696–697
 repression of somatic program, 695, 696f
Germline contribution assay, 714t
GLP, 209
Glucocorticoid receptor gene, 852
Gnas, 675–678, 675t, 682, 840f, 841
GNAT family, 899, 915t
Gnc5, 5
Grb10, 675, 675t, 678, 682
Groucho, 694
GSK3, 703
Gurdon, John, 16, 713
- H**
H1, 67, 376, 567
 domain structure, 531f
 lysine methylation site, 195
 N-formylation, 906
 table of modifications
 with known function, 954t
 with unknown function, 958t–959t
 variants, 547
H2A
 arginine methylation sites, 195
 chaperones, 583f, 584
 domain structure, 531f
 location in nucleosome core particle, 532, 533f
 phosphorylation, 263
 table of modifications
 with known function, 949t
 with unknown function, 955t
 variants, 376, 531 (*see also* Histone variants)
 chromatin location, 543–544
 chromatin properties, affect on, 544–545
 chromatin regulation, roles in, 542–543
 DNA double-strand break repair, functions in, 61, 541
 epigenetic inheritance, functions in, 545–546
 macroH2A, 7, 61, 530, 546, 546f, 548, 570, 658, 956t
 phylogenies of, 536f
 replacement by variants, 61
 X inactivation and, 546, 546f
H2A.B, 530, 546–547
H2A.Bbd, 570
H2AK118/119, 474
H2A.L, 547
H2A.X, 376, 530, 939
 chromatin remodelers, 569
 DNA double-strand break repair, functions in, 61, 541
 phosphorylation, 541–542

- sex-body formation dependence on, 541–542, 542f
- table of modifications
 - with known function, 950t
 - with unknown function, 955t
- H2A.Z, 376, 530
 - chromatin location, 543–544
 - chromatin properties, affect on, 544–545
 - chromatin regulation, roles in, 542–543
 - chromatin remodelers, 569
 - epigenetic inheritance, functions in, 545–546
 - H2A replacement with, 61
 - modifications, table of, 956t
- H2B
 - chaperones, 583f, 584
 - domain structure, 531f
 - table of modifications
 - with known function, 950t
 - with unknown function, 956t
 - variants, 547
- H2be, 826–827, 826f
- H3
 - acetylation, 581
 - amino-terminal tail role in higher-order chromatin structures, 257
 - arginine methylation sites, 195
 - cenH3 (centromeric-specific H3), 535, 535f, 537, 584
 - chaperones, 582–584, 583f
 - distribution of posttranslational modifications, 196f
 - domain structure, 531f
 - location in nucleosome core particle, 532, 533f
 - lysine methylation sites, 195
 - mutations in pediatric brain tumors, 40–42, 41f
 - at replication fork, 584, 585f
 - sequence of tail, 196f
 - table of modifications
 - with known function, 950t–952t
 - with unknown function, 957t
 - variants, 376, 531 (see also Histone variants)
 - at active chromatin, 537–539, 538f–539f
 - cell-cycle-regulated provision of, 580–581
 - at centromeres, 534–535, 535f, 537, 584
 - chromatin location of, 543
 - functions in germline, 539–541, 540f
 - genomic location of, 61, 61f
 - phylogenies of, 536f
 - in plants, 376
 - replacement, 580–581
 - replicative, 580
- H3.1, 534
 - methylation, 581
 - mutations in pediatric brain tumors, 40
 - as replicative histone, 580, 588
- H3.2, 534
 - methylation, 581
 - as replicative histone, 580, 588
- H3.3, 7, 530, 533–534, 700
 - at active chromatin, 537–539, 538f–539f
 - chromatin location of, 543
 - deposition, 588–589
 - gene mutations, 61–62
 - genomic localization of, 61, 61f
 - germline functions, 539–541, 540f
 - modifications, table of, 953t
 - mutations in pediatric brain tumors, 40
 - as replacement variant, 580–581
 - X chromosome, incorporation into, 633
- H3K4
 - CFP1 targeting of, 31
 - demethylation, 58, 58f, 351, 903–904
 - interplay with DNA methylation, 181–182
 - methylation, 230, 588, 903
 - by COMPASS, 499
 - DNA methylation and, 436–437
 - H3K4me0, 207, 212
 - H3K4me1, 84, 84f, 212
 - H3K4me2, 209, 212, 615, 744
 - H3K4me3, 21, 31–32, 66, 84, 84f, 98, 198–199, 204, 212, 214–215, 217, 219–220, 226, 232, 744, 751, 772, 809, 811, 936
- H3K9
 - demethylation, 58, 58f, 904
 - methylation, 69, 217, 581, 582f, 929
- H3K9ac, 217, 744
- H3K9me1, 209, 589, 615, 635
- H3K9me2, 589, 615, 635
 - binding of, 586
 - demethylation of, 183–184, 755
 - methylation mark, 201–202, 206, 209, 231
 - X chromosome silencing and, 611–612
- H3K9me3, 63, 65, 90, 203, 208–209, 216, 219, 231, 817–818, 822, 823f, 824, 825f
- H3K9 methylation
 - Clr4-catalyzed, 450, 455–456
 - DNA methylation and, 183–184, 436
 - in *Drosophila*, 346–348, 347f
 - heterochromatin assembly and, 452–453, 453f, 455–456
 - RITS and, 452, 453f
- H3K14ac, 217, 568
- H3K20 methylation in *Drosophila*, 347–348
- H3K23ac, 215
- H3K27
 - acetylation, 937, 939–940
 - demethylation, 58f, 721, 904
 - methylation, 904, 929, 937, 939–940
 - C. elegans* X chromosome regulation and, 612–614, 613f
 - during development, 474
 - DNA methylation and, 437
 - in malignancies, 750
 - PcG repression and, 495
 - by PRC2, 502–503
 - ubiquity of, 935–936
 - mutations and cancer, 875
- H3K27ac, 936
- H3K27me2, 612–613, 613f, 935–936, 939
- H3K27me3, 203, 476–480, 588, 612–614, 613f, 696–697, 750, 792, 793f, 811, 936
- H3K36
 - demethylation, 14, 58f, 183
 - KDM2A targeting of, 31
- H3K36me2, 31, 58f, 183, 613, 904, 936
- H3K36me3, 66, 203–204, 613–614, 626, 631, 904, 936
- H3K56ac, 581
- H3K79
 - demethylation, 15
 - methylation, 256, 614
- H3Rme2, 212, 220
- H4
 - acetylation, 581
 - arginine methylation site, 195
 - chaperones, 582–584, 583f
 - deacetylation, 581
 - domain structure, 531f
 - genes in human genome, 533
 - lysine methylation site, 195
 - at replication fork, 584, 585f
 - table of modifications
 - with known function, 953t–954t
 - with unknown function, 957t–958t
- H4K5
 - acetylation, 582f
 - deacetylation, 586, 588
- H4K12 acetylation, 582f
- H4K16
 - acetylation, 253, 254f–255f, 255–256
 - dosage compensation and, 631–633, 631f
 - MSL complex binding, 631, 631f
 - deacetylation, 253, 254f–255f, 255–256
- H4K16ac, 203, 215, 229, 608, 631–633, 631f
- H4K20me1, 203, 206, 232, 608, 904–905
- H4K20me2, 201–202, 204, 206, 221, 226, 905
- H4K20me3, 220, 817–818, 822, 823f, 824, 825f, 905
- H4K20 methylation, 588
- H13* locus, 682–683
- H19* locus, 671, 677–679, 681–682, 681f
- HAG1, 375
- Hairpin-tail defect, 669–670
- HapMap, 78
- Harvey, William, 688
- HATs. See Histone acetyltransferases
- Hbb, 513–514
- HDACs. See Histone deacetylases
- HDLP (histone deacetylase-like protein), 149, 149f
- Heart disease, histone deacetylases (HDACs) and, 159–160
- Heintz, Nathaniel, 24
- Helicases, 557, 559f, 560, 585, 627–628
- Hematopoietic stem cell (HSC), 729–730, 739, 739f
- HEN1, 385, 385f
- H-enhancer, 521
- her-1* gene, 603, 608–609
- Hermaphrodites, *C. elegans*, 601, 601f
- Heterochromatin repression, 249, 251–252, 251f
- Heterochromatin
 - assembly, 252–253, 254f
 - HM* loci, 252–253
 - RNAi in, 275–276, 278f, 450–456, 453f
 - RNA interference (RNAi) and, 445–460
 - RNA Pol II machinery in, 275–276, 278f
 - in *Schizosaccharomyces pombe*, 274–277, 278f, 450–456, 453f
 - telomere, 253, 254f
 - boundary function in budding yeast, 255f, 256
 - conservation of proteins, 449t
 - constitutive, 66
 - defined, 242
 - Drosophila*, 337–358
 - euchromatin distinction from, 73–76, 74f, 76f
 - facultative, 285–286
 - functions of, 75–76, 75f
 - maintenance of constitutive pericentromeric, 586–588, 587f
 - PRC2 and, 939
 - in *Schizosaccharomyces pombe*, 71–72, 72f, 270–286
 - boundaries, 277, 279–280, 279f
 - centromeres, 274–284, 284f
 - establishment of, 276–277
 - facultative, 285–286
 - formation at silent regions, 285–286
 - maintenance of, 277
 - RNAi and RNA Pol II in heterochromatin assembly, 275–276, 278f
 - screens to identify, 271–273, 272 types, 273, 273f
 - scnRNA-induced formation in ciliates, 328
 - silent, 66, 68
 - trans*-interaction of telomeres and perinuclear attachment of heterochromatin, 257–258, 258f–259f
 - X chromosome, 656–657
 - Xist* effect on, 648f
- Heterochromatin-associated protein 1 (HP1), 96, 301–302, 303f, 304, 459, 539, 539f, 586, 635, 929
 - chromodomains, 202, 202f, 221
- HEXIM proteins, 757
- Hi-C, 46, 523
- HIC-1 (hypermethylated-in-cancer 1) gene, 876
- HIRA (histone regulator A), 61, 588, 700
- Histone(s)
 - cell-cycle-regulated synthesis of, 580–581, 581f
 - chaperones, 567, 579, 582–584, 583f
 - conserved nature of, 55

Index

- Histone(s) (*Continued*)
deposition
after DNA replication, 533–534, 534f
of variants throughout cell cycle, 534
DNA methylation in *Neurospora crassa*,
involvement in, 301–302
domain structure, 531f
dynamics during DNA replication, 582–589
histone chaperones, 582–584, 583f
histone variants, 588–589
propagation of histone modifications, 585f,
586–588, 587f
at replication fork, 583f, 584–585
evolution of eukaryotic core histones from
archaeal histones, 531–532, 532f
gene copy number, 243
mixing parental and new, 579–589
onco-histones, 55
replication-coupled, 533
variants (*see* Histone variants)
- Histone acetylation, 117–137
bromodomain (BrD) readers, 118–119,
130–136, 130f, 132f–133f, 135f
in cancer, 898–902
erasers, 899–901
readers, 901–902
writers, 899
in ciliates, 317
during development, 700
enzymes (HATs), 120–130
erasers of, 143–165, 899–901
history of epigenetics research, 5
in longevity, 779–780
overview, 118–119
in plants, 374–375
readers (*see* BET proteins)
regulation by metabolic state, 771
timing of, 581
- Histone acetyltransferases (HATs), 57, 57f,
120–130
in cancer, 899, 915t
catalytic mechanism, 122–124, 123f
in ciliates, 317
classification, 120, 120t
CLOCK, 774–775
histone substrate binding, 124–125, 125f
inhibitors, 127–129, 128f
modification of preassembled histones, 581
MOF, 88, 624, 626–628, 626f
MOZ, 216f, 217
mutations, 915t
overview, 118–119
plants, 374–375
regulation by
autoacetylation and protein cofactors,
125–127, 127f
metabolic state, 771
in Rubinstein–Taybi syndrome, 843
structure, 120–122, 121f
- Histone code, 500
- Histone deacetylase-like protein (HDLP), 149, 149f
- Histone deacetylases (HDACs), 57, 57f, 143–165
acetyl-CoA and, 766
biological importance of, 156–160
gene transcription alteration, 157–158
human health and disease, 158–160
indirect regulation of posttranslational
modifications, 156–157
cancers and, 159, 877–878, 884, 899–901,
916t–917t
catalytic mechanisms and structures, 148f,
149–150
Class I and Class II, 149–150, 149f
Class III, 150, 150f, 151f
Class I (HDAC1, HDAC2, HDAC3, HDAC8),
146–147, 146f, 146t, 900, 916t
- Class II (HDAC4, HDAC5, HDAC6, HDAC7,
HDAC9, HDAC10), 146f, 146t, 147,
916t
- Class III (SIRT1, SIRT2, SIRT3, SIRT4, SIRT5,
SIRT6, SIRT7), 146f, 146t, 148–149,
768–770, 900, 916t–917t
- Class IV (HDAC11), 146f, 146t, 147, 916t
domain organization, 146f
in *Drosophila*, 350, 350f
families, 145–149, 146t
arginase/deacetylase superfamily, 145–147,
146t
deoxyhypusine synthase-like NAD/FAD-
binding domain superfamily,
145–147, 146t
Sir2 regulator family, 145–147, 146t
inactivation of HDAC3, 581
inhibitors, 92–93, 160–165, 843, 883f, 884,
900–901, 911
biological activity, 163
discovery, 160
mechanisms, 160–161
sirtuin inhibitors, 163–165, 164f
structure, 161f–162f
target enzyme selectivity, 161–163
maintenance of deacetylated state, 586, 588
metabolism and, 776
NAD and, 767
overview, 144–145
in plants, 374–375
regulation of activity, 152f, 154–156
posttranslational modifications, 155–156,
157f
protein complexes, 154–155
in *Schizosaccharomyces pombe*, 274
sirtuins (*see* Sirtuins)
substrates, 150–154
histones, 150–153, 153t
nonhistone, 153–154
X inactivation and, 657
- Histone deacetylation
DNA methylation and, 436
Sir2 (silent information regulator 2), 146t,
147–148, 150f, 249
- Histone demethylases (HDMs). *See also* Histone
lysine (K) demethylases (KDMs)
in cancer, 903–904, 918t–919t
discovery of, 13–15, 14f
in plants, 375
- Histone demethylation
lysine demethylation by hydroxylation,
177–178, 177f
lysine demethylation by oxidation, 175–177, 176f
in plants, 375
- Histone kinases, 57, 57f
- Histone lysine (K) demethylases (KDMs), 58, 58f,
195
in cancer, 903–904, 918t–919t
at CpG islands, 30–31, 31f
in iPSC formation, 721
regulation by α -ketoglutarate, 772, 773f
- Histone lysine (K) methyltransferases (HKMTs), 57,
57f, 171–173, 172f–173f
in cancer, 902–905, 902f, 917t–918t
Dot1p family, 171–173, 173f
G9a, 221
primordial germ cell specification and, 694
SAM and, 767, 767f
sites of methylation, 195
X inactivation and, 657
- Histone methylation
in cancer, 902–905, 902f
H3K4 writers, 903
H3K27 writers and erasers, 904
lysine erasers, 903–904
MLL, 902f, 903
- in ciliates, 317–318
during development, 700
DNA methylation and, 183–184, 231, 436–437
in *Neurospora crassa*, 301–302
Dot1p, 171–173, 173f
in *Drosophila*, 346–348, 347f
enzymes involved, 57, 57f
in longevity, 779–780
metabolism and, 772
in *Neurospora crassa* of H3K27, 304
in plants, 375
protein arginine (R) methyltransferases (PRMTs),
173–175, 174f, 175t
- readout of marks
cross talk between histone marks, 219–220
Kme marks by BAH domains, 197, 199–202,
200f
Kme marks by PHD finger domains,
197–199, 199f
methylarginine marks by Tudor modules,
209–211, 210f
methyllysine marks by expanded and paired
modules, 207–209, 208f
methyllysine marks by single “Royal Family”
modules, 202–204, 202f
methyllysine marks by tandem “Royal
Family” modules, 204–207, 205f
multivalent readout by linked binding
modules at nucleosomal level, 217
multivalent readout by linked binding
modules at peptide level, 213–217
overview, 194–197
PHD finger-bromo cassette, 217–218
unmodified arginine marks, 212–213, 213f
unmodified lysine marks, 211–212
- sites of methylation, 195
timing of, 581
- Histone methyltransferases. *See also* Histone lysine
(K) methyltransferases (HKMTs)
in cancer, 902–905, 902f, 917t–918t
DOT1L, 751
G9a, 208f, 209, 221
MMSET, 750
in plants, 375
protein arginine (R) methyltransferases
(PRMTs), 57, 173–175, 174f, 175t
methylation sites on histones, 195
SAM and, 767, 767f
X inactivation and, 657
- Histone mimics, 59, 220–221
G9a methyltransferase, 221
inflammation regulation, 758
influenza virus NS1 protein carboxyl terminus,
221
p53 tumor suppressor, 221
RNA Pol II carboxyl terminus, 221
- Histone modifications
acetylation, 117–137
biological output of, 62–66, 62f, 64f–66f
in cancer, 159, 863t, 874, 877–881, 879f,
895–919
acetylation, 898–902
arginine citrullination, 905
atypical, 905–906
cross talk, 906–910, 907f
DNA damage repair and, 908, 909f, 910
drug-discovery challenges for
histone-modifying targets,
910–914, 911f, 913t
HAT deacetylases, 916t–917t
HAT mutations, 915t
histone demethylases, 918t–919t
histone methyltransferases, 917t–918t
lysine ADP-ribosylation, 905–906
methylation, 902–905, 902f
N6-formylation, 906

- O-GlcNAcylation, 906
 - overview, 896–897, 897f
 - catalog of documented, 947–959
 - chromatin assembly and, 581–582, 582f
 - in ciliates, 317–318, 317f
 - description of, 56
 - during development, 699–700
 - DNA methylation interplay with, 181–185, 183f, 185f–186f
 - in mammals, 434, 436–437
 - in *Drosophila*, 346–348, 347f
 - enzymes involved, 56–58, 57f
 - heterochromatin silencing in *Drosophila*, 346–348
 - history of epigenetics research, 5–7, 6
 - ICF (immunodeficiency, centromeric region instability, and facial anomalies) syndrome and, 846
 - overview, 55–59
 - in plants, 369t, 374–376
 - genes involved, 369t
 - propagation of, 6–7, 6f, 585f, 586–588, 587f
 - recognition by chromatin remodelers, 568
 - resetting patterns during cellular reprogramming, 721
 - significance of, 929
 - Sir complex spreading restricted by, 256
 - sites of tail modifications, 57f
 - trithorax group (TrxG) proteins that covalently modify of nucleosomal histones, 498–501, 500f
 - X inactivation and, 656–658
 - Histone phosphorylation
 - in ciliates, 318
 - enzymes involved, 57, 57f
 - H2A.X, 541–542
 - in plants, 375–376
 - Histone regulator A (HIRA), 61, 588, 700
 - Histone ubiquitination
 - cross talk, 908–910, 909f
 - in plants, 376
 - Histone variants, 529–549, 588–589. *See also specific variants*
 - cenH3, 535, 535f, 536f, 537
 - at centromeres, 534–535, 535f, 537
 - chromatin location, 543–544
 - chromatin properties, affect on, 544–545
 - chromatin regulation, roles in, 542–543
 - chromatin remodelers and, 569–570
 - ciliate macronucleus and micronucleus, 316–317, 317f
 - deposition throughout cell cycle, 534
 - epigenetic inheritance, functions in, 545–546
 - evolution to more tightly package DNA, 547
 - genomic location of, 61, 61f
 - H2be, 826–827, 826f
 - H3.3 at active chromatin, 537–539, 538f–539f
 - H3.3 functions in germline, 539–541, 540f
 - human disease and, 547–548
 - overview, 60–62, 530
 - phylogenies of, 536f
 - in plants, 376
 - X inactivation and, 546, 546f
 - History of epigenetics research, 1–8
 - reprogramming and induced pluripotency, 713–716, 713f
 - HKMTs. *See* Histone lysine (K) methyltransferases
 - HMG proteins, 376, 930
 - HM loci, 245, 247f, 248–249, 251–253, 255, 257–258, 261, 263–264
 - heterochromatin at, 251f, 252–253, 256
 - HML, 245, 247f, 252, 257, 258f, 261, 264
 - HMR, 245, 247f, 251–252, 256–257, 264
 - HO endonuclease, 245, 247f, 263, 557
 - Homologous recombination, in yeast, 243, 263
 - Homology-dependent gene silencing in ciliates, 318–319
 - Honeybees, 98
 - HOTAIR, 5–6, 18–20, 19f, 81, 94, 230, 232, 478
 - HOTTIP, 230
 - Hoxal, 694
 - Hoxa9, 217–218, 903
 - Hoxb1, 694
 - HOXC, 18
 - HOXD, 18–19, 520
 - Hox genes, 491–492
 - Polycomb-group (PcG) proteins and, 466, 474, 478, 480, 483
 - regulation of transcription, 492, 492f
 - TrxG proteins and, 492
 - HP1 (heterochromatin-associated protein 1), 96, 301–302, 303f, 304, 459, 539, 539f, 586, 635, 929
 - chromodomains, 202, 202f, 221
 - HP1a, 344–345, 344f, 347, 347f, 354–358, 354f
 - HP1 β , 822
 - Hrp1/3, 286
 - HS5-1 enhancer, 814, 817
 - HS7 enhancer, 814, 817
 - HSC. *See* Hematopoietic stem cell
 - Human disease, 831–853
 - chromatin structure in *cis*, related to, 847–851, 847t, 849f
 - in facioscapulohumeral dystrophy (FSHD), 849f, 850–851
 - fragile-X syndrome, 834, 847t, 848–850, 848f–849f
 - thalassemias, 847–848
 - chromatin structure in *trans*, related to, 841–847, 842t
 - α -thalassemia X-linked mental retardation, 547–548, 845
 - ICF (immunodeficiency, centromeric region instability, and facial anomalies) syndrome, 845–846
 - Kabuki syndrome, 846–847
 - recurrent hydatidiform mole, 842–843
 - Rett syndrome, 843–845, 844f
 - Rubinstein–Taybi syndrome, 843
 - Schimke immuno-osseous dysplasia (SIOD), 846
 - cystic fibrosis, 834–835
 - DNA methylation-related, 197, 833
 - environmental and epigenetic interactions, 851–852, 851f
 - diet and epigenotypes in aging and disease, 851–852
 - fetal or infant experiences and epigenotypes, 852
 - epigenetic factors in, 93–96, 94f
 - genomic imprinting disorders, 836–841, 837t
 - Angelman syndrome, 836–838, 836f, 837t, 838f
 - Beckwith–Wiedemann syndrome, 837t, 839–840, 840f
 - Prader–Willi syndrome, 674, 836–839, 836f, 837t, 838f
 - pseudohypoparathyroidism, 837t, 840–841, 840f
 - Silver–Russell syndrome, 837t, 840
 - histone deacetylases (HDACs) and, 158–160
 - histone methylation-related, 196
 - histone variants and, 547–548
 - induced pluripotent stem cell (iPSC) technology and, 726–728, 728f
 - overview, 832–834, 834f
 - Rett syndrome, 222, 438–439, 843–845, 844f
 - studies uncovering role of epigenetics, 834–835
 - trithorax group (TrxG) proteins and, 503
 - uniparental disomy (UPD) in, 832, 835, 835f, 837–838, 840–841
- Human Genome Project, 48
- Hypermethylated-in-cancer 1 (HIC-1) gene, 876
- Hypermethylation
 - in cancer, 91, 866–872, 866f–867f, 869t, 871t
 - classes of hypermethylated genes, 869t
 - determination of functional importance in cancer, 871–872, 871t
 - of gene promoters, 869–872, 878–880, 879f
 - technology used to identify methylation patterns, 870–871
- Hypomethylation
 - in cancer, 90–91, 865–866, 866f
 - chromosome instability and, 438
- Hypomorphic alleles, from ENU mutagenesis, 406–408
- I**
- I-BET, 36–38, 38f
- IBM1 (INCREASE IN BONSAI METHYLATION), 375
- ICEs (imprint control elements), 674–677, 675t, 676f
- ICF (immunodeficiency, centromeric region instability, and facial anomalies) syndrome, 845–846
- ICR1/2
 - Beckwith–Wiedemann syndrome and, 839, 840f
 - Silver–Russell syndrome and, 840
- IDH. *See* Isocitrate dehydrogenase (IDH) enzymes
- IESs (internal eliminated sequences), 320–321, 323–325, 324f–325f, 327
- IFN (interferon), 754–755
- IGCR1 (intergenic control region 1), 747f, 748–749
- IGF2. *See* Insulin-like growth factor 2
- IgH, 739, 743–749, 747f
- Ig κ , 743–746
- IgL, 739, 743
- Ikaros, 739
- Imitation switch (ISWI), 558–560, 559f, 562–563, 562f, 567–569, 635, 910
- Immunity, 737–758
 - adaptive immune system, 739, 739f
 - B-cell development, 739f
 - diversity of immune response, 755
 - inflammatory response, chromatin-mediated control of, 751–754, 753f
 - lineage commitment in lymphoid system, 739–741, 740f
 - control of lymphoid lineage commitment, 740–741, 740f
 - lymphoid gene priming in hematopoietic progenitors, 739–740, 740f
 - lineage plasticity, 741–742, 741f
 - conversion of mature B cells into functional T cells, 742
 - reprogramming by ectopic transcription factors, 741–742
 - lymphoid malignancies, 749–751, 749f
 - overview, 738
 - T-cell development, 739f
- V(D)J recombination, 742–749
 - chromatin-mediated RAG function at recombination centers, 744
 - control of ordered by CTCF and cohesin, 748–749
 - developmental regulation of antigen receptor gene rearrangements, 742–744, 743f
 - monoallelic recombination by homologous pairing of immunoglobulin loci, 744–746, 745f
 - spatial control by locus contraction, 746–748, 747f

Index

- Immunity (*Continued*)
 subnuclear relocation of antigen receptor loci in developing lymphocytes, 745f, 746
- Immunoglobulin, 739
- Imprint control elements (ICEs), 674–677, 675t, 676f
- Imprinting. *See* Genomic imprinting
- INCREASE IN BONSAI METHYLATION (IBM1), 375
- Induced pluripotency, 711–731
 developmental potential of a cell, assessment of, 714, 714t
 history of research, 713–714, 713f
 overview, 712
- Induced pluripotent stem cells (iPSCs), 89–90, 89f, 688, 711–731
 cell proliferation, 722
 disease research applications, 726–730
 cell therapy, 729–730, 729f
 genetic modification of iPSCs, 726, 727f
 modeling in culture dish, 726–728, 728f
 efficiency of reprogramming somatic cells to, 17
 epigenetic memory, 722
 equivalency to embryonic stem cells, 730
 generation of, 716–718, 716f
 genetically unmodified, 717
 integration-free, 717
 overview, 712
 reprogramming factor-free, 717
 X inactivation, 724
- Inflammation
 chromatin-mediated control of response, 751–754, 753f
 gene expression regulation by signal-induced RNA elongation, 755–757, 756f
 histone deacetylases (HDACs) and, 160
 inhibition of bromodomain-containing proteins, 36–38, 38f
 regulation and histone mimicry, 758
 transcriptional noise, 755
- Influenza virus NS1 protein carboxyl terminus, 221
- ING2, 198–199, 219
- ING4, 220
- Inheritance
 epigenetic, 98–101, 100f
 maternal, 699
 resetting *versus* transgenerational in plants, 800–801
- Ink4a/Arf*, 722
- Inner cell mass, 690–691, 690f, 697, 697f, 699, 701–704, 713
- Ino80, 562–563, 562f, 565–566, 569
- Insulin-like growth factor 2 (*IGF2*)
 Beckwith–Wiedemann syndrome and, 839, 840f
 genomic imprinting and, 671, 673, 675–682, 675t
 loss of imprinting (LOI), 873
 Silver–Russell syndrome and, 840
- Intangible variation, 416–417, 417f
- Interferon (IFN), 754–755
- Intergenic control region 1 (IGCR1), 747f, 748–749
- Internal eliminated sequences (IESs), 320–321, 323–325, 324f–325f, 327
- Internet resources, 943–945
- Intersex states, 643
- Inverted repeat RNA, 796, 796f
- In vitro differentiation, 714t
- iPSCs. *See* Induced pluripotent stem cells
- IRX3* gene, 764
- Isocitrate dehydrogenase (IDH) enzymes, 98
 hypermethylation of, 868
 mutations and cancer, 772, 868, 873–874
- ISWI (imitation switch), 558–560, 559f, 562–563, 562f, 567–569, 635, 910
- J**
- JAK2, 219
- Jarid2, 87–88
- JIL1, 350, 627, 635
- JMJD2A, 205f, 206
- JQ1, 33–35, 34f
- JUMONJI-C-DOMAIN (JmjC) proteins, 14–15, 14f, 375, 768
- Jumonji-containing histone demethylases, 177–178, 177f, 183
- K**
- Kabuki syndrome, 846–847
- Kaiso, 223, 224f
- Kap1, 133, 133f, 214, 217–218
- KATs. *See* Histone acetyltransferases (HATs)
- Kcnq1*, 478, 479f, 675–680, 675t, 682, 839, 840f
- KDM2A, 30–32, 31f
- KDMs. *See* Histone lysine (K) demethylases
- Kinetochores, *Schizosaccharomyces pombe*, 280–284, 282f, 284f
- Kis* gene/protein, 496–498
- Kit* locus, 413–414
- Klf1 (Krüppel-like factor 1), 513–514
- Klf4, 722, 724, 726
- Kluyveromyces lactis*, 249
- Kme-Kac cross talk, 220
- Kme-Kub cross talk, 220
- Kme-Rme cross talk, 220
- Kme-Sph cross talk, 219
- kohtalo* (*kto*), 501
- Kriaucionis, Skirmantas, 24
- KRYPTONITE (KYP), 231
- L**
- L3MBTL1, 206, 207f, 221, 232
- Lamin B receptor (LBR), 824, 825f
- Largazole, 161, 161f
- LDL (lysine-specific histone demethylase-LIKE) proteins, 375
- LEAFY COTYLEDON2* (*LEC2*), 478
- Leukemia, 33, 749–751, 749f, 877–878, 885
- Leukemia inhibitory factor (LIF), 724–726
- light* gene, 353–354
- Lin28, 724
- lincRNAs (long intergenic noncoding RNAs), 18, 230
- LINE (long-interspersed repeats), 655–656, 655f
- Lineage switching, transcription factors and, 715–716
- Linker histones. *See also* H1
 N-formylation, 906
 in plants, 376
- Linné, Carl von, 365
- Lipid A, 751
- Lipopolysaccharide (LPS), 37, 751–754, 752f–753f
- LIS-1, 802
- lncRNAs (long noncoding RNAs), 18–20, 81, 83, 83f, 94, 226, 503, 932. *See also* HOTAIR; Xist
 enhancer RNAs distinct from, 21
 genomic imprinting and, 675–678, 680, 682
- Locus control regions, 415
- Longevity, metabolism and, 778–781, 781f
- Long intergenic noncoding RNAs (lincRNAs), 18, 230
- Long-interspersed repeats (LINE), 655–656, 655f
- Looping interactions, 519–524
 associations between groups of active and inactive loci, 522–523
 building chromatin loops, 524
 CTCF role in, 524, 817–818
 gene regulation and, 524
 between genes and regulatory elements, 519
- interchromosomal interactions, 521–522, 522f
 at mouse globin loci, 519–520, 519f
 between regulatory elements, 520–521
 topologically associating domains (TADs), 523
- Loss of imprinting (LOI), 873
- LOXL2 (lysyl oxidase-like 2 enzyme), 906
- LPS (lipopolysaccharide), 37, 751–754, 752f–753f
- LSD1 (lysine-specific histone demethylase 1), 13–15, 14f, 19, 58, 176–177, 176f, 211–212, 351, 768, 903
- LSD2 (lysine-specific histone demethylase 2), 58, 437, 768
- LSH2 protein, 437
- Lung disease, histone deacetylases (HDACs) and, 160
- Lymphocytes. *See also* B cells; T cells
 subnuclear relocation of antigen receptor loci in developing, 745f, 746
- Lymphogenesis, transcriptional control of, 740f
- Lymphoid malignancies, 749–751, 749f
- Lyon, Mary, 646
- Lysine (K) acetyltransferases (KATs). *See* Histone acetyltransferases (HATs)
- Lysine ADP-ribosylation in cancer, 905–906
- Lysine demethylation
 by hydroxylation, 177–178, 177f
 by oxidation, 175–177, 176f
- Lysine marks, readout of
 Kme marks by BAH domains, 197, 199–202, 200f
 Kme marks by PHD finger domains, 197–199, 199f
 methyllysine marks by expanded and paired modules, 207–209, 208f
 ADD domains, 207–209, 208f
 Ankyrin repeats, 209
 Pygo PHD finger and BCL9, 209
 methyllysine marks by single “Royal Family” modules, 202–204, 202f
 chromodomains, 202–203, 202f
 PWWP domains, 202f, 203–204
 Tudor domains, 202f, 203
 methyllysine marks by tandem “Royal Family” modules, 204–207, 205f
 tandem chromodomains, 204, 205f
 tandem MBT repeats, 206–207, 207f
 tandem Tudor domains, 204–206, 205f
 unmodified lysine, 211–212
 PHD fingers, 211–212
- Lysine methylation of histone tails, 195–196
- Lysine (K) methyltransferases (KMTs), 57, 57f, 171–173, 172f–173f
 SAM and, 767, 767f
 trithorax group (TrxG) proteins and, 494–495, 499, 502
 X inactivation and, 657
- Lysine-specific histone demethylase 1 (LSD1), 13–15, 14f, 19, 58, 176–177, 176f, 211–212, 351, 768, 903
- Lysine-specific histone demethylase 2 (LSD2), 58, 437, 768
- Lysine-specific histone demethylase-LIKE (LDL) proteins, 375
- Lysyl oxidase-like 2 enzyme (LOXL2), 906
- M**
- MacroH2A, 7, 61, 530, 546, 546f, 548, 570, 658, 956t
- Macronuclear-destined sequences (MDSs), 320–321, 327
- Maintenance of epigenetic information, 575–593
 chromatin structure inheritance, 579–589
 DNA methylation, 577–579, 578f
 overview, 576
 replication timing, 589–593, 591f
- Males absent on the first (MOF), 88, 220, 624, 626–628, 626f

- Male-specific lethal (MSL), 203, 621, 623–626, 628–634, 629f–632f, 634f, 636
- Malignant brain tumor (MBT) repeats, 206–207, 207f
- Mammals
- development
 - early germline development in mammals, 691–694, 692f–693f
 - epigenetic reprogramming cycle, 690
 - life cycle, genetic and epigenetic continuum of, 689–691
 - X inactivation, regulation of, 646–647
- DNA methylation in, 423–440
- as cell memory system, 425
 - CpG islands, 428–429, 430f
 - demethylation, 429–432
 - de novo methylation, 425–428, 426f
 - diseases and, 437–439
 - DNA methyltransferase functions, 427t
 - establishment of patterns, 425–429, 427f
 - future directions, 439–440
 - gene expression regulation by, 433–434
 - interplay with histone modification, 434, 436–437
 - mapping methylation, 429b
 - overview, 424
- dosage compensation, 641–662
- overview, 642
 - sex determination and, 643–644, 643f
 - X inactivation, 646–660
 - X-linked genes, up-regulation of, 644–645, 646f
 - X reactivation and reprogramming, 660–662
- genetic imprinting, 667–684
- Polycomb-group (PcG) proteins in, 466f, 468t, 469f, 472–473, 478, 480–483, 482f
- sex determination, 643–644, 643f
- X inactivation, 646–660
- chromatin modification, 647
 - cycle of inactivation and reactivation, 647f
 - developmental regulation, 646–647
 - genes escaping inactivation, 647–648
 - identification of inactive X in females, 646
 - initiation of inactivation, 649–654
 - order of events, 658–659, 659f
 - overview, 646–649
 - propagation and maintenance, 654–660
 - reactivation and reprogramming, 660–662
 - X inactivation center (Xic), 648, 652f
 - Xist* (X-inactive-specific transcript), 648–656, 648f, 650f–652f, 655f, 658–662, 659f–661f
- Maternal inheritance, 699
- Mating types
- ciliates, 315, 332, 332f
 - Neurospora crassa*, 297
 - Schizosaccharomyces pombe*, 270, 271, 285
 - yeast, 245, 247f
- Mating type switching, in yeast, 245, 247f
- MAT* locus, 245, 247f, 263
- MATs (methionine adenosyltransferases), 767, 772
- MBDs. *See* Methyl-CpG binding domain (MBD) family
- MBT (malignant brain tumor) repeats, 206–207, 207f
- McClintock, Barbara, 3, 365, 387
- Mcm2-7 complex, 264
- MDSs (macronuclear-destined sequences), 320–321, 327
- MeCP2. *See* Methyl-CpG binding protein complex 2
- MEDEA (MEA), 377, 470, 471f, 478, 481
- Mediator complex, 501, 503, 524, 524f
- Meiotic silencing
- in *Neurospora crassa*, 305–308, 306f–307f
 - X chromosome in *C. elegans* males, 611–612
- Meiotic silencing of unpaired DNA (MSUD), 450, 612
- MeIP (methylated DNA immunoprecipitation), 429b, 439
- Meisetz*, 698
- Meristems, 364, 366
- Mesenchymal-to-epithelial transition, 720
- MES histone modifiers, 612–614, 613f
- Messenger RNA (mRNA), transfection with, 717
- MET1, 799, 799f
- Metabolic signaling to chromatin
- aging and senescence, 778–781, 781f
 - circadian epigenome, 772–778, 774f–775f
 - enzymes, 768–770
 - PARPs, 770
 - sirtuins, 768–770, 776–777
 - histone acetylation, 771
 - histone methylation, 772
 - metabolites, 765–768, 765f
 - acetyl-CoA, 765–766, 765f–766f
 - FAD, 768
 - NAD, 766–767, 766f, 777–778, 778f
 - SAM, 767–768, 767f
 - oncogenic mutations, 772, 773f
 - overview, 764
- Metabolism, epigenetic response to, 96–98, 97f
- Methionine adenosyltransferases (MATs), 767, 772
- Methylarginine marks, readout by Tudor modules, 209–211, 210f
- canonical Tudor domains, 209–210, 210f
 - expanded Tudor domains, 210–211, 210f
- Methylated DNA immunoprecipitation (MeIP), 429b, 439
- Methylation, 169–187. *See also* DNA methylation; Histone methylation
- in ciliates, 317
 - maintenance, 178, 179f, 299, 300–301, 425–428, 426f
 - overview, 170
 - sites on histones, 195
- Methylation marks, readout of, 193–232
- cross talk between histone marks, 219–220
 - Kme-Kac cross talk, 220
 - Kme-Kub cross talk, 220
 - Kme-Rme cross talk, 220
 - Kme-Sph cross talk, 219
 - DNA fully methylated 5mCpG, 221–223, 222f
 - methylcytosine-binding (MBD) proteins, 222–223, 222f
 - methylcytosine-binding Zn-finger proteins, 223
 - DNA hemimethylated 5mCpG, 223–226, 224f–225f
 - mammalian SRA domains, 223–225, 224f–225f
 - plant SRA domains, 225–226
- future challenges, 226–232
- chemical biology approaches to designer nucleosomes, 227–228
 - chromatin-based therapeutic modalities, 231–232
 - functional role for noncoding regulatory RNAs, 230–231
 - histone mark readout at nucleosomal level, 228–229
 - linking histone and DNA methylation, 231
 - readout of oxidative 5mC DNA adducts, 229–230
 - technological developments at genome-wide level, 226–227
- Kme marks by BAH domains, 197, 199–202, 200f
- Kme marks by PHD finger domains, 197–199, 199f
- methylarginine marks by Tudor modules, 209–211, 210f
- canonical Tudor domains, 209–210, 210f
 - expanded Tudor domains, 210–211, 210f
- methyllysine marks by expanded and paired modules, 207–209, 208f
- ADD domains, 207–209, 208f
 - Ankyrin repeats, 209
 - Pygo PHD finger and BCL9, 209
- by single “Royal Family” modules, 202–204, 202f
- chromodomains, 202–203, 202f
 - PWWP domains, 202f, 203–204
 - Tudor domains, 202f, 203
- by tandem “Royal Family” modules, 204–207, 205f
- tandem chromodomains, 204, 205f
 - tandem MBT repeats, 206–207, 207f
 - tandem Tudor domains, 204–206, 205f
- Methyltransferase. *See also* DNA methyltransferases (DNMTs); Histone methyltransferases
- Dnmt1, 178, 179f, 425
 - Dnmt3 family, 178, 180–181, 180f

Index

- Methyltransferase (*Continued*)
G9a, 221
lysine (K) methyltransferases (KMTs), 57, 57f, 171–173, 172f–173f
trithorax group (TrxG) proteins and, 494–495, 499, 502
maintenance, 178, 179f, 425–428, 426f
MET1, 799, 799f
protein arginine (R) methyltransferases (PRMTs), 57, 173–175, 174f, 175t
X inactivation and, 657
Microarrays, for identification of DNA methylation patterns, 870–871
Minichromosomes, yeast, 243
miRNAs (micro RNAs)
biogenesis, 447–448
in plants, 379–381
biogenesis and function, 379–381, 380f
mobile, 28
silencing, 796, 797f
silencing, 796, 797f
Mit1, 567
Mitotic kinases, 57
Miwi-like proteins, 698
MLE, 627–628
MLH1
epigenetic silencing, 875
epimutations in, 841
MLL1, 66, 66f, 84, 84f, 182, 183f, 212, 214f, 215, 218, 218f, 220, 494, 776
in cancer, 902f, 903
MLL2 gene/protein, 750–751, 847
Mobile silencing, 799–800, 800f
Model systems for studying epigenetics, 51–53, 51f
modENCODE
Drosophila and, 346, 351, 353
posttranslational modification linkages, 195
Modifiers of murine metastable epialleles (Mommies), 397–406
Agouti viable yellow allele, influence on expression at, 402–404, 403f
described, 397, 398f
dominant screen, 397, 399t–400t, 490
importance of Mommies in development, 400–402
MommeD1, 400–402
MommeD10, 402
MommeR1, 406
paternal effect genes, 404, 406f
point of action of *MommeD* mutants, 401f
recessive screen, 404, 406
MOF (males absent on the first), 88, 220, 624, 626–628, 626f
Mommies. *See* Modifiers of murine metastable epialleles
Morgan, Thomas Hunt, 2
MORPHEUS' MOLECULE 1 (MOM1), 378
Mouse
 β -globin loci, 519–520, 520f
as model system, 51f, 53
Polycomb-group (PcG) proteins in, 466f, 468t, 469f, 478, 480, 482–483, 482f
reprogrammable mice, 717–718
Mouse models to study epigenetics, 395–417
epigenetic phenomena in inbred mouse colonies, 409–417
environmental effects on metastable epialleles, 416, 416f
intangible variation, 416–417, 417
paramutation-like effects, 413–414
parent-of-origin effects, 411–412, 412f
position effects, 415
repeat-induced gene silencing, 415–416
transgenerational epigenetic inheritance via the gamete, 412–413, 413f–414f
variable expressivity, 410–411
variegation, 409–410
future directions, 417
identification of modifiers of epigenetic reprogramming, 397–409
ENU mutagenesis production of hypomorphic alleles, 406–408, 407f
screen for genes involved in X inactivation choice, 408
screen for modifiers of murine metastable epialleles (Mommies), 397–406
metastable epialleles and reporter alleles, 405t
modifiers of murine metastable epialleles (Mommies)
Agouti viable yellow allele, influence on expression at, 402–404, 403f
described, 397, 398f
dominant screen, 397, 399t–400t, 490
importance of Mommies in development, 400–402
paternal effect genes, 404, 406f
point of action of *MommeD* mutants, 401f
recessive screen, 404, 406
screens for, 397–406
overview, 395–417
MOZ, 216f, 217
MPPs (multipotent progenitors), 739
MSL (male-specific lethal), 203, 621, 623–626, 628–634, 629f–632f, 634f, 636
MSUD (meiotic silencing of unpaired DNA), 450, 612
MTA1, 199
Muller, H.J., 2, 623, 623f
Müller's ratchet, 644
Multiple myeloma, 750
Multipotent, defined, 714t
Multipotent progenitors (MPPs), 739
murine CDK5 activator binding protein IAP (*mCABPA^{IAP}*), 411
Mutations. *See also specific genes*
cancer and, 94f, 861, 861t, 862f, 863t–864t, 864–865, 868
dynamic, 834
histone H3 mutations in pediatric brain tumors, 40–42, 41f
methylation affect on rate of, 868
methyl CpG as hot spots for, 437–438
MYB, 901
MYOD1 (myogenic differentiation 1), 16–17
MYST, 120t, 121–122, 124–126, 129, 627, 774, 899, 915t
- N**
N6-formylation, in cancer, 906
NAD (nicotinamide adenine dinucleotide), 96–98, 97f, 766–767, 766f, 777–778, 778f
Nanog, 696, 703, 717, 720–722, 724
NAP-1 chaperone, 583f, 584
NASP (nuclear autoantigenic sperm protein), 584
ncRNAs (noncoding RNAs), 50, 72–73, 478–480, 479f, 503, 932. *See also specific RNAs*
enhancer RNAs (eRNAs), 21–23, 22f
epigenetic control of gene expression, 18–20, 19f
epigenetic inheritance and, 100–101
extended gene concept and, 81–83, 82f
functional role for, 230–231
function in response to environmental stimuli, 98
in MSL complex, 625
percentage of transcriptome, 19
plant mobile small RNAs, 27–29, 28f
roX (RNA on X), 627–628, 630
spermatogenesis and, 698
Xist (*see Xist*)
neo gene, 325
Nervous system, 807–827
neurogenesis, epigenetic regulation of, 809–811, 809f–810f
olfactory sensory neurons, 817–826, 821f, 823f, 825f
overview, 808
protocadherin (*Pcdh*) promoter choice, epigenetic regulation of, 811–818
Neuronal stem cells (NSCs), 809, 809f, 811
Neurospora crassa, 295–309
DNA methylation, 69, 298–304
components of methylation machine, 302f
histone involvement in, 301–302
maintenance methylation, 299, 300–301
modulators of, 302, 304
overview, 298–299
epigenomic features of genome, 303f
genome, 297–298
histone H3K27 methylation, 304
history and features of, 297–298
images of, 297f
life cycle, 297, 298f
meiotic silencing, 305–308, 306f–307f
as model system, 51f, 52
quelling, 304–305, 305f
RIP (repeat-induced point mutation), 299–300, 299f–300f, 308–309
RNAi, 296, 302
Next-generation sequencing, for identification of DNA methylation patterns, 439, 871
NF- κ B, 755, 780
Nicotinamide adenine dinucleotide (NAD), 96–98, 97f, 766–767, 766f, 777–778, 778f
NLRP7 gene, 843
NMNAT1 (nicotinamide nucleotide adenyltransferase), 96
Noncoding RNAs. *See* ncRNAs (noncoding RNAs)
NORs (nucleolar organizer regions), 512
Notch1 gene/protein, 740–742, 750
Np95, 588
nPAO (nuclear polyamine oxidase), 13
NSCs (neuronal stem cells), 809, 809f, 811
NSD1/2, 904
NT-ES cells, 715, 715f
Nuclear architecture, long-range chromatin interactions and, 510–514
chromosomal translocations, 514–515, 515f
nonrandom genome organization in nucleus, 510
nuclear periphery, physical interaction with, 510–512, 511f
spatial gene clustering, 512–514, 514f
Nuclear autoantigenic sperm protein (NASP), 584
Nuclear periphery, role in gene regulation, 510–512, 511f
Nuclear polyamine oxidase (nPAO), 13
Nuclear transfer experiments, 670, 670f, 713–714, 715f
Nucleolar organizer regions (NORs), 512
Nucleolus, 512–513
Nucleosome-organizing proteins, in plants, 370t–371t, 377–378
Nucleosome remodeler/deacetylase complexes (NuRD), 218, 566, 568–569, 739
Nucleosome remodeling, 555–571
chromatin assembly and organization, 566–568
consequences of ATP-dependent, 558f
in development, 570
discovery of, 557–559
DNA methylation and, 569
DNase I-hypersensitivity analysis, 557, 557f
histone modifications recognition by chromatin remodelers, 568
histone variants and chromatin remodelers, 569–570
history of epigenetics research, 5

- mechanism of, 560–562, 561f
overview, 556
posttranslational modification, regulation by, 568–569
promoters and, 563, 565–566, 565f
remodelers as regulators of transcription, 563–566
in *Schizosaccharomyces pombe*, 286
Nucleosome remodeling factor (NURF), 66, 198, 214, 559, 559f, 635
Nucleosomes
archaeal, 531–532
assembly, 533–534, 534f
H3–H4 partitioning during, 585f
chemical biology approaches to designer, 227–228
density, 934–935
disruption during replication, 577, 579, 585
histone mark readout at nucleosomal level, 228–229
histone marks and chromatin differentiation, 930
histones H3 and H2A occupancy, 532, 533f, 544–545
location of histones H3 and H2A, 532, 533f
structure, 55, 56f
trithorax group (TrxG) proteins that covalently modify nucleosomal histones, 498–501, 500f
NuRD. *See* Nucleosome remodeler/deacetylase complexes
NURF (nucleosome remodeling factor), 66, 198, 214, 559, 559f, 635
O
O6-MGMT, epigenetic silencing of, 875
Oct3, 579, 702
Oct4, 579, 702, 717, 720–722, 724, 726
ODR-1 gene, 98
O-GlcNAc transferase (OGT), 906
O-GlcNAcylation in cancer, 906
Ohno, Susumu, 644–646
Olfactory receptor, 808
chromatin structure and nuclear organization of OR clusters, 822
epigenetic regulation of OR choice, 818–826
monoallelic OR expression, 820–822, 821f
protocadherin (Pcdh) promoter choice, epigenetic regulation of, 811–818
spatial organization of genes, 824–826, 825f
Olfactory sensory neurons, 817–827, 821f, 823f, 825f
Olfactory system, anatomy and genetics of, 818–820, 819f
Olf151, 101
Oncogene, 860, 861
Oncogenesis. *See also* Cancer
epigenetic deregulation in, 873
isocitrate dehydrogenase (IDH) mutations and, 873–874
mismatching of epigenetic machinery recruited by oncogenic translocation products, 877–878
tumor suppressor gene silencing, 874–876
Onco-histones, 55
1000 Genomes project, 78
Oocyte, 688, 689f, 698–700
ORC (origin recognition complex), 200, 248, 252, 264
Orcl, 199–201, 200f, 226, 249, 264
OSA, 496
Oxidation of 5-methylcytosine, 70, 229–230, 431–432, 440
Oxytricha, 314, 319–322, 320f, 329, 331. *See also* Ciliates
P
p16 epigenetic silencing, 874–875
p19 protein, as viral suppressor of RNA silencing, 795, 795f
p53-binding protein (53BP1), 204, 205f
p53 gene/protein
acetylation by CBP, 930
apoptosis and, 722
deacetylation, 153–154
methylation affect on mutation rate, 868
posttranslational modifications, 221
p300, 21, 22f, 120t, 121–122, 121f, 123f, 125–129, 125f, 127f, 128f
PAD family, 905
PAF1, 758
Pancreatic neuroendocrine tumors (PanNETs), 548
Paramecium, 51f, 52, 314–315, 318–324, 320f, 326–329, 332, 332f. *See also* Ciliates
Paramutation-like effects, 413–414
Parent-of-origin effects, 411–412, 412f
Parkinson's disease, histone deacetylases (HDACs) and, 159
PARPs, 569–570, 770, 905–906
Parthenogenesis, 688, 699
Pax5, 740–742, 740f–741f, 748
PB1 (Polybromo 1) protein, 131
PCAF, 120–122, 120t, 124–126, 128–129, 130f, 131–132
Pcdh. *See* Protocadherin
PCGF (Polycomb group Ring finger), 86
PcG proteins. *See* Polycomb-group (PcG) proteins
PCNA (proliferating cell nuclear antigen), 533, 534f, 582, 583f, 586, 588
PCR
in 5C technology, 518–519
in 4C technology, 518
inverse, 518
Pediatric brain tumors, histone H3 mutations in, 40–42, 41f
P element, 341, 345, 355
PER, 773, 774f, 775
PEV. *See* Position effect variegation
pgc (polar granule component), 695
PGC7/STELLA, 680, 680f, 692, 694
PGCs. *See* Primordial germ cells
PHD finger
multivalent readout by linked binding modules at peptide level, 215–217, 216f
Pygo PHD finger and BCL9, 209
readout of Kme marks by, 197–199, 199f
readout of methyllysine marks by expanded and paired modules, 209
readout of unmodified arginine marks, 212–213, 213f
readout of unmodified lysine marks, 211–212
vernalization and, 792
PHD finger-bromo cassette, 217–218
as E3 SUMO ligase, 217–218
multivalent readout by linked binding modules at nucleosomal level, 217
multivalent readout by linked binding modules at peptide level, 214–215, 214f
as regulatory platform, 218, 218f
PHERES1 (PHE1), 470, 471f, 479f, 481
PHF8, 184–185, 185
PHO (pleiohomeotic), 477, 477f
PHO84 gene, 565
Phosphatases, 57–58, 57f
regulation of histone deacetylases (HDACs), 155–156
Phosphorylation
in ciliates, 317
of histone deacetylases (HDACs), 155–156
RNA Pol II carboxy-terminal domain, 66, 66f
piggyback transposase, 322
piRNAs, 82, 101
biogenesis, 448, 448f
in *Drosophila*, 72, 355–356, 356f, 449–450
Piwi (P-element-induced wimpy testis), 72, 210–211, 355–356, 449–450, 458–459
Plants, 363–389
assays for epigenetic control in, 373f
chromatin formation and chromatin remodeling genes, 370t–371t, 377–378
DNA methylation in, 372, 384–387, 385f, 577–578
DNA modification, 368, 369t, 372–374
cytosine demethylation, 373–374
DNA glycosylases, 373–374
DNA methyltransferases, 372
genes involved, 369t
methylcytosine-binding proteins, 374
proteins required for methyl group donor synthesis, 374
RNA-directed DNA methylation and heterochromatin formation, 384–387, 385f
RNAi-mediated, 456–458, 457f
epigenetic regulation in response to environment, 787–803
FLC locus, 788–793, 790f–791f, 793f–794f
genome structure, 802
heritable legacy of induced changes, 803
overview, 788
resetting *versus* transgenerational inheritance, 800–801
transgenerational regulation in response to stress, 801–802
transient regulation in response to stress, 801
vernalization, 788–793, 790f–791f, 793f–794f
virus-induced gene silencing, 794–800, 795f–800f
histone modification, 369t, 374–376
associated with transcriptional gene silencing, 386
histone acetyltransferases, 374–375
histone deacetylases, 374–375
histone demethylases, 375
histone methyltransferases, 375
histone phosphorylation, 375–376
histone ubiquitination, 376
histone variants, 376
life cycle, 366, 367f
mobile small RNAs, 27–29, 28f
as models for epigenetic research, 365–368
epigenome similarity to mammals, 365–366
genetic attributes of plants, 368, 369t–372t
overview, 365
unique aspects of plant development, 366–368, 367f
molecular components of chromatin in, 368, 372–378
histone-modifying enzymes and histone variants, 369t, 374–376
nucleosome-organizing proteins, 377–378
Polycomb-group proteins and interacting components, 369t–370t, 376–377
regulators of DNA modification, 368, 369t, 372–374
nucleosome-organizing proteins, 370t–371t, 377–378
chromatin assembly factors, 378
chromatin-remodeling complexes, 377–378
Polycomb-group (PcG) proteins in, 466–467, 466f, 468t, 469, 469f, 471f, 474, 478–481, 479f, 791–792, 791f
position effect variegation (PEV), 356–357
silencing in, 72, 365, 378–388
amplification and spreading of siRNA-mediated, 387–388, 388f

Index

- Plants (*Continued*)
genes involved, 371t–372t
histone modifications associated with
transcriptional gene silencing, 386
miRNA biogenesis and silencing, 379–381, 380f
non-cell-autonomous silencing, 387–388
RNA-directed DNA methylation (RdDM), 384–387, 385f
RNA-mediated silencing of endogenous genes, 386–387
siRNA-mediated as genome defense strategy, 382–384
trans-acting siRNAs (tasiRNAs), 381–382, 382f
transitivity, 387, 388f
vernalization, 789–793, 790f–791f, 793f–794f
virus-induced gene silencing, 794–800, 795f–800f
- Plasmids, yeast, 243
Plasmodesmata, 366
Plasticity, defined, 714t
Pleiohomeotic (PHO), 477, 477f
Pluripotency, 688, 691, 697, 703–704
alternative states of, 724–726, 725f
defined, 713, 714t
development of potential of a cell, assessment of, 714, 714t
induced, 711–731
Pluripotent stem cell lines, 714–715
Pluripotent stem cells, 687–705
derivation of, 702–703, 702f
epigenetic properties of, 703–704
germ cell development from, 697–698
overview, 688
reprogramming capacity of, 704
sources of, 715f
- Plzf* (*Promyelocytic zinc finger*) gene, 408–409
PNBs (prenucleolar bodies), 512
polar granule component (*pgc*), 695
Poly(AD-ribosyl)ation, 770
Polybromo 1 (PBI) protein, 131
Polycomb-group (PcG) proteins, 375, 376–377
in *C. elegans*, 466–467, 466f, 468t, 469f
cellular memory and, 465, 465f
DNA binding proteins, 468t
in *Drosophila*, 466–468, 466f, 468t, 469f, 470, 473–478, 477f, 480, 483
genes involved, 369t–370t
genetic identification of group, 466–467, 466f
Hox genes and, 466, 474, 478, 480, 483
in mammals, 466f, 468t, 469f, 472–473, 478, 480–483, 482f
ncRNAs (noncoding RNAs), binding to, 478–480, 479f
overview, 83–87
in plants, 369t–370t, 376–377, 466–467, 466f, 468t, 469, 469f, 471f, 474, 478–481, 479f, 791–792, 791f
promoters, functioning of protein complexes at, 472f
silencing and, 463–484
antisilencing, preventing heritable repression by, 476
chromatin silencing marks, 467–476
overview, 464
repression in development and disease, 480–483, 482f–483f
targeting PcG complexes to silenced genes, 476–480, 477f, 479f
vernalization, 791–792, 791f
stem cell fate, maintenance of, 482–483, 483f
trithorax group (TrxG), interactions with, 502–503
- Polycomb-group response element (PRE), 464, 474, 475f, 476–478, 477f, 929
- Polycomb group Ring finger (PCGF), 86
Polycomb repressive complex 1 (PRC1), 588
components of, 468t, 469f, 473–474
evolutionary conservation of, 469f
overview, 84, 86–87, 87f
targeting to silenced genes, 476–477, 477f
X inactivation and, 87–88, 88f, 657
- Polycomb repressive complex 2 (PRC2), 408, 588
in cancer, 750
cell proliferation, control of, 481–482, 482f
chromatin-modifying activity, 470, 472–473
components of, 467–470, 468t, 469f
development, dynamic functioning during, 473
evolutionary conservation of, 467–470, 469f
EZH2, 750, 904, 910, 930
heterochromatin and, 939
lncRNAs (long noncoding RNAs) and, 18–19
loss of, effect of, 940
ncRNAs (noncoding RNAs), binding to, 478–480, 479f
overview, 84, 85–87, 86f
in plants, 376–377, 467, 469, 469f, 471f, 478, 481, 482f
targeting to silenced genes, 476–478
TrxG proteins and, 502–503
X inactivation and, 87–88, 88f, 480, 657
- Polyploidy, in plants, 364, 366, 368
Poly(AD-ribose) polymerases (PARPs), 569–570, 770, 905–906
- Polytene chromosomes, 345–346, 497f, 538f, 566, 635
- Position effects, 415
Position effect variegation (PEV), 4, 242, 356–357
described, 337–342
in *Drosophila*, 337–345, 340f, 348, 349f, 353, 356, 357
locus control regions and, 415
in plants, 356–357
in *Schizosaccharomyces pombe*, 272
screens to identify, 272f
- Postranscriptional gene silencing (PTGS), 71, 448–449, 452, 455. *See also* Silencing
in plants, 365, 378–379, 383, 383f
- Posttranslational modifications (PTMs). *See also* Histone modifications; *specific enzymes*
catalog of documented histone modifications, 947–959
chromatin assembly and, 581–582, 582f
histone acetylation, 117–137
of histone deacetylases (HDACs), 155–156, 157f
in human disease, 833
indirect regulation by histone deacetylases, 156–157
methylation marks, readout of, 193–232
regulation of nucleosome remodelers, 568–569
- Potato spindle tuber viroid, 450
Prader–Willi syndrome, 674, 836–839, 836f, 837t, 838f
- PRC1. *See* Polycomb repressive complex 1
PRC2. *See* Polycomb repressive complex 2
Prdm9, 698
Prdm14, 695
PRE. *See* Polycomb-group response element
Preformationism, 2
Prenucleolar bodies (PNBs), 512
Prereplicative complex, 264
PRG-1, 449
Primordial germ cells (PGCs)
gametogenesis, 698–699
overview, 688
pluripotent cell lines from, 703
specification, mechanisms regulating, 691–699
Blimp1 role in, 694–695
early germline development in mammals, 691–694, 692f–693f
- epigenetic programming regulation after specification, 696–697
repression of somatic program, 695, 696f
- PRMTs. *See* Protein arginine (R) methyltransferases
- Proliferating cell nuclear antigen (PCNA), 533, 534f, 582, 583f, 586, 588
- Promoters
CpG island, 32, 577
CpG-low, 751–752
hypermethylation in cancers, 869–872, 878–880, 879f
lnc RNAs (long noncoding RNAs), 21, 22f
methylation of promoter CpG islands, 438
nucleosome remodelers, 563, 565–566, 565f
paused, Polycomb-group (PcG) connection to, 474–476, 475f
PcG and TrxG protein complexes functioning at, 472f
Pol II recruitment to, 65–66, 66f
protocadherin (Pcdh), 811–818
short nucleosome-depleted region, 939
virus-induced silencing, 797–798, 798f–799f
- Promyelocytic zinc finger* (*Plzf*) gene, 408–409
- Protein arginine deiminases, 57f, 58
Protein arginine (R) methyltransferases (PRMTs), 57, 173–175, 174f, 175t
methylation sites on histones, 195
SAM and, 767, 767f
- Protein kinase C α , 768
Protocadherin (Pcdh), 808, 811–818
alternative splicing, 814, 815f
clustered genes, 811, 812f, 813–814
epigenetic regulation of promoter choice, 811–818
expression, epigenetic control of, 814, 816f, 817–818
gene regulation, 814
isoforms, 814, 815f, 818
- Pseudohypoparathyroidism, 837t, 840–841, 840f
PTGS. *See* Postranscriptional gene silencing
PTMs. *See* Posttranslational modifications
Pws, 675–676, 675t
PWWP domains, 202f, 203–204
Pygo PHD finger, 209
Pyrosequencing, 429b
- Q**
Qde-2-associated RNAs (qiRNAs), 304–305
Quelling, in *Neurospora crassa*, 304–305, 305f
- R**
Rad2, 262–263
Rad21, protocadherin (Pcdh) expression and, 817–818
RAG proteins, 199, 219, 742, 743f, 744, 745f, 746
Rap1 (repressor activator protein 1), 248, 252–253, 254f, 257, 258f, 259
ras, 861
rasiRNAs (repeat associated small interfering RNAs), 355–356
RBP2 (RETINOBLASTOMA BINDING PROTEIN 2), 473
RdBP. *See* RNA-dependent RNA polymerase
RdDM (RNA-directed DNA methylation), 384–387, 385f
RDM (REQUIRED FOR DNA METHYLATION), 386
RDRC, 454
Recombination, V(D)J, 742–749
Recurrent hydatidiform mole, 842–843
Regulatory elements
looping between elements, 520–521
looping between genes and, 519

- Remodeling and spacing factor (RSF), 567, 635
Repeat associated small interfering RNAs (rasiRNAs), 355–356
- Repeat DNA
in heterochromatin, 242
rDNA repeats and Sir2, 261–263, 262f
RIP (repeat-induced point mutation) in *Neurospora crassa*, 299–300, 299f–300f, 308–309, 450
in telomeres, 259–260, 260f
- Repeat-induced gene silencing, 415–416
Repeat-induced point mutation (RIP) in *Neurospora crassa*, 299–300, 299f–300f, 308–309
- REPLICATION FACTOR C1, 376
- Replication fork
histones dynamics at, 583f, 584–585
nucleosome assembly at, 534f
- Replication origin choice, regulating, 264
- REPLICATION PROTEIN A2 (RPA2), 376
- Replication timing, 589–593, 591f
asynchronous, 592–593
gene expression correlation to, 591–592
patterns of, 589–590
regulation of, 590–591, 591f
- Repressor activator protein 1 (Rap1), 248, 252–253, 254f, 257, 258f, 259
- REPRESSOR OF SILENCING 1 (ROS1), 373–374
- Reprogramming, 16–17, 17f
cell cultures for, generating, 717–718, 718f
contributions of individual factors to, 722, 724
defined, 714t
disease research applications, 726–730
efficiency of somatic cells to iPSCs, 17
history of research, 713–716, 713f
induced pluripotency and, 711–731
iPSCs generation, 716–718, 716f
mechanisms underlying iPSC formation, 718–726
activation of pluripotency genes, 720, 721f
deterministic *versus* stochastic models, 718–720, 719f
molecular changes, 720–723
resetting methylation patterns, 721–722
silencing of somatic genes, 720
molecular changes during, 720–723
with recombinant proteins, 717
reprogrammable mice, 717–718
screen for reprogramming factors, 716–717, 717f
- REQUIRED FOR DNA METHYLATION (RDM), 386
- Resources, Internet, 943–945
- RETINOBLASTOMA BINDING PROTEIN 2 (RBP2), 473
- Retinoblastoma (Rb) protein, 481
- Rett syndrome, 222, 438–439, 843–845, 844f
- RHA (RNA helicase A), 627
- Ribosomal RNA, spatial clustering of genes, 512–513
- Rif1, 253, 254
- RING1, 482, 482f
- RIP (repeat-induced point mutation) in *Neurospora crassa*, 299–300, 299f–300f, 308–309
- RISC (RNA-induced silencing complex), 448–449
- RITS (RNA-induced transcriptional silencing) complex, 71, 72f, 446, 448, 452–456, 453f
- R-loop, 83
- RNA
central dogma and, 50
pervasive roles of nuclear RNA molecules, 932
- RNA-dependent RNA polymerase (RdRP), 379
small RNA biogenesis, 447–448, 448f
- RNA-directed DNA methylation (RdDM), 384–387, 385f
- RNA helicase A (RHA), 627
- RNAi. *See* RNA interference
- RNA-induced silencing complex (RISC), 448–449
- RNA-induced transcriptional silencing (RITS) complex, 71, 72f, 446, 448, 452–456, 453f
- RNA interference (RNAi), 50, 937, 939. *See also* Silencing
in *Arabidopsis*, 456–458, 457f
in *Caenorhabditis elegans*, 53
chromatin modifications in animals, 458–459
in ciliates, 72, 314, 326, 328, 330f, 331
conservation of proteins, 449t
heterochromatin assembly and, 275–276, 278f, 445–460
link to transcriptional gene silencing (TGS), 450
Neurospora crassa, 296, 302
overview, 71–73, 72f, 447–450, 447f
RNA-silencing pathways, 448–450
small RNA biogenesis, 447–448, 448f
in plants, 72, 365, 456–458, 457f
recruitment of chromatin-modifying enzymes, 455–456
in *Schizosaccharomyces pombe*, 275–276, 278f, 450–456, 453f
spermatogenesis and, 698
- RNA on X (roX), 627–628, 630
- RNA polymerase I (RNA Pol I)
in plants, 384
rRNA and, 513
- RNA polymerase II (RNA Pol II), 379–380, 380f, 634
dosage compensation complex and, 608
enhancer RNA transcription, 21, 22f, 23
in fission yeast, 458
heterochromatin assembly in
Schizosaccharomyces pombe, 275–276, 278f
histone mimicry, 221
LPS and, 753, 753f
modification of carboxy-terminal domain, 66, 66f, 221
paused promoters, Polycomb-group (PcG) connection to, 474–476, 475f
in plants, 384–385
recruitment to promoters, 66–66, 66f
signal-induced RNA elongation, 756–757, 756f
spatial gene clustering and, 512–514
variants, 797, 797f
- RNA polymerase III (RNA Pol III)
in plants, 384
tRNA gene transcription, 513
- RNA polymerase IV (RNA Pol IV)
in plants, 384–386, 385f, 458
in RNA-directed DNA methylation (RdDM) pathway, 385–386, 385f
siRNA biogenesis, 797f
- RNA polymerase V (RNA Pol V), 376
in plants, 384–386, 385f, 458
in RNA-directed DNA methylation (RdDM) pathway, 385–386, 385f
siRNA biogenesis, 797, 797f
- RNA–RNA targeting model, 455
- RNA silencing. *See also* Silencing
genes involved in plants, 371t–372t
pathways, 448–450
in virus-infected plants, 794–800, 795f–800f
Rnf12 gene/protein, 652, 652f
rolled gene, 353–354
- ROS1 (REPRESSOR OF SILENCING 1), 373–374
- roX (RNA on X), 627–628, 630
- “Royal Family” modules
readout of methyllysine marks by single, 202–204, 202f
chromodomains, 202–203, 202f
PWWP domains, 202f, 203–204
Tudor domains, 202f, 203
- readout of methyllysine marks by tandem, 204–207, 205f
tandem chromodomains, 204, 205f
tandem MBT repeats, 206–207, 207f
tandem Tudor domains, 204–206, 205f
- RPA2 (REPLICATION PROTEIN A2), 376
- RSC, 560, 561f, 562, 565–566, 569
- RSF (remodeling and spacing factor), 567, 635
- Rsx*, 648–649
- Rtt109, 120t, 121–124, 121f, 123f, 126–127, 127f, 129
- Rubinstein–Taybi syndrome, 843
- S**
- Saccharomyces cerevisiae*, 241–264
genetic and molecular tools of, 243
H3 amino-terminal tail role in higher-order chromatin structures, 257
heterochromatic repression, 249, 251–252, 251f
heterochromatin assembly, 252–253, 254f
HM, 252–253
telomere, 253, 254f
heterochromatin boundary function, 255f, 256
histone acetylation, 771
histone deacetylases (HDACs), 145–146, 148
inheritance of epigenetic states, 261
life cycle, 245, 246f
mating type switching, 245, 247f
as model system, 51f, 52
nuclear periphery, role in gene regulation, 512
overview of epigenetics in, 242
secondary functions of Sir proteins and silent chromatin, 261–264, 263f
chromosomal cohesion, 263
homologous recombination prevention, 263
replication factors, link to, 263–264
replication origin choice, regulating, 264
suppression of recombination, 261–263
telomere length regulation, 263
- Sir2 deacetylation of histone H4K16, 253, 254f–255f, 255–256
- Sir protein structure and evolutionary conservation, 248–249
- spatial gene clustering of tRNA genes, 513
- telomere looping, 258–259
- telomere position effect (TPE), 243, 244f, 248, 253
- trans*-interaction of telomeres and perinuclear attachment of heterochromatin, 257–258, 258f–259f
variable repression at natural subtelomeric domains, 259–261, 260f
- Sad-1* gene, 307, 307f
- S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE, 374
- S-adenosyl L-methionine (SAM), 98, 767–768, 852
- SAGA, 60, 205–206, 565f, 568
- SAHA, 160, 161f, 162f
- SAHFs (senescent-associated heterochromatin foci), 780–781
- SATB1, 660, 660f
- Scanning RNA (scnRNA) in ciliates, 326–328, 327f
- Schimke immuno-osseous dysplasia (SIOD), 846
- Schizosaccharomyces pombe*, 269–289
central domain chromatin, 280–284, 282f
centromeres, 274–284
abnormal structure from defective heterochromatin, 284f
epigenetic inheritance of functional centromere state, 281, 283
sister-centromere cohesion, 283–284
chromatin boundaries, 277, 279–280, 279f
genomics and epigenomics in, 288–289
heterochromatin, 71–72, 72f, 270–286

Index

- Schizosaccharomyces pombe* (Continued)
boundaries, 277, 279–280, 279f
centromeres, 274–284, 284f
establishment of, 276–277
facultative, 285–286
formation at silent regions, 285–286
maintenance of, 277
organization of chromosome regions, 451f
RNAi in heterochromatin assembly,
275–276, 278f, 450–456, 451f, 453f
RNA Pol II in heterochromatin assembly,
275–276, 278f
screens to identify, 271–273, 272
types, 273, 273f
kinetochores, 280–284, 282f, 284f
life cycle, 271, 271f, 277–297
mating types, 270, 271, 285
as model system, 51f, 52
nuclear organization, 286–288, 287f
nucleosome remodeling, 286
silent chromatin, 285–286
cenH regions, 285
facultative heterochromatin, 285–286
mating-type loci, 285
telomeres, 285
scnRNA (scanning RNA) in ciliates, 326–328, 327f
SCNT (somatic cell nuclear transfer), 713–714, 715f
sdc genes/proteins, 603–604
sea-1, 602
Secreted frizzled-related protein (*SFRP*) gene,
875–876
Senescence, metabolism and, 778–781, 781f
Senescent-associated heterochromatin foci (SAHFs),
780–781
SET1, 66, 66f
SET2, 66, 66f
SetDBT, 581, 582f
Sex determination
Caenorhabditis elegans, 602f
Drosophila, 625f
mammals, 643–644, 643f
Sex lethal (*Sxl*) gene/protein, 624–625, 625f
SFRP (secreted frizzled-related protein) genes,
875–876
SGF29, 205–206, 205f
SHH1, 205, 205f
shh (*Sonic hedgehog*) signaling, 482–483, 483f
SHOOTMERISTEMLESS (STM), 470, 471f
Short RNAs, in ciliates, 314
SHREC histone deacetylase complex, 453, 453f
Signal-induced RNA elongation, 755–757, 756f
Silence elements, yeast, 261
Silencing
in cancer, 860, 861, 872–881, 877t
cis-acting silencing in imprinted gene clusters,
680–683, 681f
in *Drosophila*, 72, 346–348
heterochromatic repression, 249, 251–252, 251f
heterochromatin silencing in *Drosophila*, 346–
348
homology-dependent in ciliates, 318–319
silencing induced by dsRNA, 319
transgene-inducing silencing, 318–319
iPSC formation and, 720
meiotic silencing
in *Neurospora crassa*, 305–308, 306f–307f
X chromosome in *C. elegans* males, 611–612
meiotic silencing of unpaired DNA (MSUD),
450
mobile, 799–800, 800f
in plants, 365, 378–388
amplification and spreading of siRNA-
mediated, 387–388, 388f
genes involved, 371t–372t
histone modifications associated with
transcriptional gene silencing, 386
miRNA biogenesis and silencing, 379–381,
380f
mobile small RNAs and, 27–29, 28f
non-cell-autonomous silencing, 387–388
RNA-directed DNA methylation (RdDM),
384–387, 385f
RNA-mediated silencing of endogenous
genes, 386–387
siRNA-mediated as genome defense strategy,
382–384
trans-acting siRNAs (tasiRNAs), 381–382,
382f
transitivity, 387, 388f
vernalization, 789–793, 790f–791f,
793f–794f
virus-induced gene silencing, 794–800,
795f–800f
Polycomb-group (PcG) proteins and, 463–484
antisilencing, preventing heritable
repression by, 476
chromatin silencing marks, 467–476
overview, 464
repression in development and disease,
480–483, 482f–483f
targeting PcG complexes to silenced genes,
476–480, 477f, 479f
postranscriptional gene silencing (PTGS), 71,
448–449, 452, 455
in plants, 365, 378–379, 383, 383f
repeat-induced gene silencing, 415–416
RNA-directed, 71–73, 72f, 384–387, 385f
RNA-induced silencing complex (RISC),
448–449
RNA-induced transcriptional silencing (RITS)
complex, 446, 448
RNA-silencing pathways, 448–450
transcriptional gene silencing (TGS), 71, 446,
448–449, 454–457, 459
virus-induced gene silencing pathway (VIGS),
365, 383
X chromosome (*see* X inactivation)
Silent information regulator 1 (Sir1)
heterochromatin silencing and, 252
roles of, 248
Silent information regulator 2 (Sir2)
chromosome cohesion and, 263
deacetylation of histone H4K16, 253, 254f–255f,
255–256
heterochromatin silencing and, 252
histone deacetylation, 146t, 147–148, 150f, 249
replication origin choice, regulating, 264
roles of, 248
structure and evolutionary conservation of, 249
suppression of recombination, 262–263, 262f
Silent information regulator 3 (Sir3)
BAH domain, 199, 201
heterochromatin silencing and, 252
homologous recombination prevention, 263
replication origin choice, regulating, 264
roles of, 248
structure and evolutionary conservation of, 249
telomere–telomere interaction and, 258
Silent information regulator 4 (Sir4)
heterochromatin silencing and, 252–253
scaffold role of, 248–249
structure and evolutionary conservation of, 248
Silent information regulatory proteins (Sirs)
family trees, 250f
in *Saccharomyces cerevisiae*, 261–264, 263f
chromosomal cohesion, 263
homologous recombination prevention, 263
replication factors, link to, 263–264
replication origin choice, regulating, 264
suppression of recombination, 261–263
telomere length regulation, 263
secondary functions, 261–264, 263f
silent *HM* mating loci and, 245
structure and evolutionary conservation,
248–249
Silver–Russell syndrome, 837t, 840
SIOD (Schimke immuno-osseous dysplasia), 846
siRNAs, 71–72, 72f
biogenesis, 447–448, 448f
dsRNA synthesis and siRNA generation, 454–455
hairpin, 454
in plants
amplification and spreading of siRNA-
mediated silencing, 387–388, 388f
mobile, 27–29, 28f
siRNA-mediated silencing as genome
defense strategy, 382–384
trans-acting siRNAs (tasiRNAs), 381–382,
382f
transitivity, 387, 388f
in *Schizosaccharomyces pombe*, 71, 276, 277
transposable elements as source of, 29
virus-derived, 27–29, 28f
virus-induced gene silencing, 794–797,
795f–797f
SIRs. *See* Silent information regulatory proteins
SIRT1, 96–97, 768–770, 776–777, 900, 916t
SIRT2, 900.908t
SIRT3, 769, 900, 917t
SIRT6, 769–770, 777, 779–780, 900, 917t
SIRT7, 769–770, 900, 917t
Sirtuins
in cancer, 900, 916t–917t
catalytic mechanisms and structures, 150, 150f,
151f
chromatin regulation and, 768–770
domain organization, 146f
inhibitors, 163–165, 164f
NAD and, 97, 777–778
overview, 148–149
regulation, 155–156
substrates
histone, 153, 153t
nonhistone, 153–154
skuld (*skd*), 501
Small nuclear ribonucleoprotein (SNRPN), in
Prader–Willi syndrome, 838–839
Small RNAs. *See also* miRNAs; siRNAs
biogenesis, 447–448, 448f
in ciliates
DNA elimination linked to, 326
scanning (scnRNA), 326–328, 327f
trans-nuclear comparison of whole genomes
by, 326
heterochromatin assembly in association with
RNAi effector complex, 452–454
plant mobile, 27–29, 28f
Qde-2-associated RNAs (qiRNAs), 304–305
quelling in *Neurospora crassa*, 304–305
Smarca5, 406f, 407
Smchd1 gene/protein, 401, 660
SMN (survival of motor neuron), 209, 210f
SND1, 210–211, 210f
Snf2 family, 559–560, 559f
SNRPN (small nuclear ribonucleoprotein), in
Prader–Willi syndrome, 838–839
Soft X-ray tomography (SXT), 824, 825f
Somaclonal variation, 366
Somatic cell nuclear transfer (SCNT), 713–714, 715f
Somatic cells, reprogramming, 88–90, 89f
Sonic hedgehog (*shh*) signaling, 482–483, 483f
Sonneborn, T.M., 315
Sox2, 722, 724
SOX17, 875–876
Spatial gene clustering, 512–514, 514f
nucleolus, 512–513
transcription factories, 513–514, 514f
tRNA, 513

- Sperm, histone variants and, 547
Spermatogenesis, 698–699
Spinal motor atrophy, 727–728, 728f
SRA domains
 mammalian, 223–225, 224f–225f
 plant, 225–226
SRRP1 (STRUCTURE-SPECIFIC RECOGNITION PROTEIN), 376
SRY gene, 643
SSH1, 212
STAT5, 743
Stem cells
 derivation of, 702–703, 702f
 differentiation of, 697–698, 697f
 epiblast (EpiSCs), 724–726
 epigenetic properties of, 703–704
 fate, maintenance of, 482–483, 483f
 hematopoietic (HSC), 729–730, 739, 739f
 iPSCs (see Induced pluripotent stem cells)
 neuronal stem cells (NSCs), 809, 809f, 811
 overview, 688
 plants, 364, 366
 reprogramming capacity of, 704
STM (SHOOTMERISTEMLESS), 470, 471f
Stress, epigenetic regulation in plants in response to
 transgenerational regulation, 801–802
 transient regulation, 801
STRUCTURE-SPECIFIC RECOGNITION PROTEIN (SRRP1), 376
Stylonychia, 319–321
Su(var), 339, 340f, 341t, 342–348, 347f, 350–351, 350f, 354f, 357
SUC2, 557
SUMO, 257–258
Suprachiasmatic nucleus, 772, 774
Survival of motor neuron (SMN), 209, 210f
SUVH5, 225–226, 225f
Suz12, 409
swc (*super sex combs*), 474
SWI2/SNF2, 377–378, 458, 495–498, 496f, 502–504, 560, 563
Swi6, 275, 277, 279–280, 283–284, 450, 452–455
SWINGER, 791
Swi/Snf, 60, 557–558, 560, 562–566, 568, 904
SWR1, 562–563, 569
SXL (*Sex lethal*) gene/protein, 624–625, 625f
SXT (soft X-ray tomography), 824, 825f
- T**
TADs (topologically associating domains), 523
TAF1, 130–131, 130f, 134
Tahiliani, Mamta, 24–25
TALE (transcription activator-like effector) proteins, 726, 727f
tasiRNAs (*trans*-acting siRNAs), 381–382, 382f
TBE (telomere-bearing element) family
 transposases, 322
T-cell receptor (TCR), 739, 742–743, 746, 748–749
T cells
 conversion of mature B cells into functional T cells, 742
 development, 739f, 741
TDRD3, 210, 210f, 221
Telomerase, 253, 257
Telomere-bearing element (TBE) family
 transposases, 322
Telomere position effect (TPE), 243, 244f, 248, 253
Telomeres
 ALT (alternative lengthening of telomeres)
 phenotype, 548
 function of, 68
 heterochromatin assembly, 253, 254f
 heterochromatin formation in
 Schizosaccharomyces pombe, 285
 length regulation, 263
 looping, 258–259
 Schizosaccharomyces pombe, 270
 trans-interaction of telomeres and perinuclear attachment of heterochromatin, 257–258, 258f–259f
 variable repression at natural subtelomeric domains, 259–261, 260f
Ten-eleven translocation (TET) family
 DNA demethylation, 431–432, 431f, 700
 domain structure of Tet family proteins, 432f
 5-hydroxymethylcytosine (5hmC) and, 24–26, 26f
 hypermethylation of, 868
 oxidation of 5mC, 24–25, 26f, 70, 431–432, 431f, 440
 regulation by α -ketoglutarate, 772, 773f
Teratocarcinoma, 714
Teratoma formation, 714t, 729
TET proteins. See Ten-eleven translocation (TET) family
Tetrahymena, 313–322, 320f, 324–329, 331. See also Ciliates
 as model system, 51f, 52
 RNAi, 72
Tetraploid complementation assay, 714t, 715
TGS. See Transcriptional gene silencing
Thalassemias
 α -thalassemia X-linked mental retardation, 547–548, 845
 $\delta\beta$, 847–848
 $\gamma\delta\beta$, 847–848
Therapeutic cloning, 698
Thrifty phenotype hypothesis, 852
Thymine DNA glycosylate, 25
TNF α , 755
Topoisomerases, nucleosome remodeling and, 286
Topologically associating domains (TADs), 523
Totipotency, 688, 689, 691, 699, 713, 714t
TPE (telomere position effect), 243, 244f, 248, 253
TRAMP, 452
Trans-acting siRNAs (tasiRNAs), 381–382, 382f
Transcription
 aberrant activation, 481–482
 dynamics of inflammatory response, 751–754, 752f–754f
 histone deacetylase (HDAC) alteration of, 157–158
 of nucleosome-free regions, 937, 939
 nucleosome remodelers as regulators of, 563–566
 trithorax group (TrxG) roles in eukaryotic, 494–495
Transcription activator-like effector (TALE) proteins, 726, 727f
Transcriptional gene silencing (TGS), 446, 448–449, 454–457, 459
 histone modifications associated with in plants, 386
 Polycomb-group (PcG) proteins and, 463–484
 Schizosaccharomyces pombe and, 71
 virus-induced silencing of promoters, 798–799, 799f
Transcriptional noise, 755
Transcriptional regulation, by trithorax group (TrxG), 489–504
Transcription factories, 513–514, 514f
Transcription factors
 DNA methylation interference with binding, 433
 lineage reprogramming by ectopic, 741–742
 lineage switching and, 715–716
 model to distinguish euchromatin from heterochromatin, 75–76, 76f
 pluripotent state maintenance of embryonic stem cells, 722, 723f
Transdifferentiation, defined, 714t
Transfection with messenger RNA, 717
transformer (*tra*) genes, 624
Transgenerational epigenetic inheritance via the gamete, 412–413, 413f–414f
Transitivity, 387, 388f
Translocations, 514–515, 515f
Transposable elements
 in *Arabidopsis*, 458
 in *Drosophila*, 341–342, 342f, 345, 355–356
 epigenetic control of, 802
 as siRNA source, 29
Transposases
 in ciliates, 321–322
 piggyback, 322
 telomere-bearing element (TBE) family, 322
Trichostatin A (TSA), 160–162, 161f, 162f, 301–302
TRIM24, 212, 214–215, 214f
TRIM33, 212, 214–215, 214f
Triplet repeats
 CGG repeat, in fragile-X syndrome, 848, 849f
 in facioscapulohumeral dystrophy (FSHD), 849f, 850–851
 in fragile-X syndrome, 848, 849f, 850
Trithorax group (TrxG), 375, 489–504
 biochemical functions, 494t, 501
 cellular memory and, 465, 465f, 491, 491f
 chromatin and, 495–501, 496f–497f, 500f
 ATP-dependent chromatin remodeling, 495–498, 496f
 chromosomal distribution of, 497f
 cohesin and, 501
 connection to general transcription machinery, 501
 covalent modification of nucleosomal histones, 498–501, 500f
 developmental cell fate transformation, 493f
 in *Drosophila*, 491f–493f, 492–494, 494t, 496–499, 496f–497f, 501–504
 human disease and, 503
 identification of genes, 492–494
 mutations blocking derepression of Hox genes in PcG mutants, 493f
 noncoding RNAs, 503
 overview, 83–84, 84f, 490
 Polycomb-group (PcG) proteins, interactions with, 502–503
 promoters, functioning of protein complexes at, 472f
 roles in eukaryotic transcription, 494–495
Trithorax-like (*Trl*), 502
tRNA gene clustering, 513
TSA (trichostatin A), 160–162, 161f, 162f, 301–302
Tsix, 648, 652–653, 658
Tudor domains/modules
 readout of methylarginine marks by, 209–211, 210f
 canonical Tudor domains, 209–210, 210f
 expanded Tudor domains, 210–211, 210f
 readout of methyllysine marks by single, 202f, 203
 readout of methyllysine marks by tandem, 204–206, 205f
Tumors. See also Cancer
 involvement of DNA methylation machinery in tumorigenesis, 880–881
 loss of imprinting (LOI) in, 873
 progression, 872–876, 872f, 874f
Tumor suppressor genes, 860, 861
 hypermethylation of gene promoters, 869–872
 silencing in oncogenesis, 874–876
TWII gene, 326
Twilp, 327–328
- U**
UBE3A, 838
Ubiquitination of histones

Index

- Ubiquitination of histones (*Continued*)
 histone cross talk, 908–910, 909f
 in plants, 376
Ubx (*Ultrabithorax*), 491
UHRF1, 178, 179f, 184
 methylation marks and, 204, 212–213, 213f,
 215–217, 216f, 219, 223–224, 231
 SRA domains, 223–224, 225f
UNC669, 232
Uniparental disomy (UPD), 669–670, 669f, 832,
 835, 835f, 837–838, 840–841
Unipotent, defined, 714t
URA3 reporter gene, 243, 244f
UTX, 721, 750, 936, 937
- V**
Variegation, 409–410
 at endogenous alleles in the mouse, 409–410
 mechanisms, underlying molecular, 410
 at transgenes in the mouse, 410
Vernalization, 788–793, 790f–791f, 793f–794f
 adaptation to different climates, 792–793
 Polycomb silencing, 791–792, 791f
 quantitative nature of, 792, 793f
VERNALIZATION2 (VRN2), 467, 469–470, 471f,
 791
Viral suppressor of RNA silencing (VSR), 29, 795,
 795f
Viroid, 365, 450
Virus
 siRNAs, virus-derived, 27–29, 28f
 transgenes, 717
Virus-induced gene silencing (VIGS), 365, 383,
 794–800, 795f–800f
 establishment and maintenance phases of,
 798–799, 799f
 mobile silencing, 799–800, 800f
 promoter silencing, 797–798, 798f–799f
V(D)J recombination, 742–749
 chromatin-mediated RAG function at
 recombination centers, 744
 control of ordered by CTCF and cohesin,
 748–749
 developmental regulation of antigen receptor
 gene rearrangements, 742–744, 743f
 monoallelic recombination by homologous
 pairing of immunoglobulin loci,
 744–746, 745f
 spatial control by locus contraction, 746–748,
 747f
 subnuclear relocation of antigen receptor loci in
 developing lymphocytes, 745f, 746
von Hippel, Peter, 930–931
VRN2 (VERNALIZATION2), 467, 469–470, 471f,
 791
vtd (*verthandi*), 501
- W**
Waddington, Conrad, 16, 688
Warburg effect, 97
WD40 motifs, 211f, 212
WDR5, 211f, 212, 721
Web sites, 943–945
- Weismann's barrier, 16
white mutation in *Drosophila*, 339, 340f, 341, 342f,
 343, 345, 349, 349f, 352–353, 355,
 415
Williams–Beuren syndrome, 402
Wilmut, Ian, 16
Wnt signaling, epigenetic silencing of, 875
Wuschel (*WUS*), 478
- X**
Xce (X controlling element), 653
X chromosome. *See also* Dosage compensation; X
 inactivation
 reactivation and reprogramming, 660–662
 in experimental reprogramming, 661–662,
 661f
 in normal development, 660–661
 regulation in *Caenorhabditis elegans*, 599–616
 in germline development, 609–611, 610f
 global repression, 609–611
 meiotic silencing in males, 611–612
 MES histone modifiers and, 612–614, 613
 overview, 600, 603f
 paternal X inactivation in embryos, 614–
 616, 615f
 X-linked genes, compensatory up-regulation
 of, 609, 609f
 X-linked genes, down-regulation of, 605,
 607–609, 607f
 transient pairing of two, 745
X controlling element (*Xce*), 653
X inactivation, 459, 701, 703
 histone variants and, 546, 546f
 history of epigenetics research, 4
 imprinted inactivation, regulation of, 649, 650f,
 653
 induced pluripotent stem cells (iPSCs), 724
 initiation of inactivation in mammals, 649–654
 evolutionary variation in regulatory
 mechanisms, 653–654
 imprinted *versus* random inactivation, 649–
 653, 650f–652f
 switching modes of regulation, 653
 interchromosomal interactions and, 521, 522f
 interrelated mechanisms, 7–8
 in mammals, 646–650
 chromatin modification, 647
 cycle of inactivation and reactivation, 647f
 developmental regulation, 646–647
 genes escaping inactivation, 647–648
 identification of inactive X in females, 646
 initiation of inactivation, 649–654
 order of events, 658–659, 659f
 overview, 646–649
 propagation and maintenance, 654–660
 reactivation and reprogramming, 660–662
 X inactivation center (Xic), 648, 652f
 Xist (X-inactive-specific transcript), 648–
 656, 648f, 650f–652f, 655f, 658–
 662, 659f–661f
 MommeD1 and, 400–402
 overview, 87–88, 88f
 paternal in early embryos, 614–616, 615f
 Polycomb-group proteins and, 480
 propagation and maintenance of inactive state in
 mammals, 654–660
 booster elements facilitating spread,
 655–656, 655f
 chromatin modifications, 656–657
 chromatin structure, higher-order, 657–658
 order of events, 658–659, 659f
 spreading of *Xist* RNA, 654–655
 Xist-mediated silencing, 659–660, 660f
 random inactivation, regulation of, 649–653,
 650f–652f
 choice, 653
 counting, 649–652
 replication timing and, 593
 screen for genes involved in choice, 408
X inactivation center (Xic), 87, 88f, 521, 522f
 genes and regulatory elements in, 652f
 in mammals, 648, 652f
Xist (X-inactive-specific transcript), 87, 88f, 230,
 408, 479–480, 521, 724
 down-regulation, 701, 703
 in mammals, 648–656, 648f, 650f–652f, 655f,
 658–662, 659f–661f
 silencing mediated by, 659–660, 660f
 spreading of *Xist* RNA, 654–655
X-linked genes
 in *C. elegans*
 compensatory up-regulation of, 609, 609f
 down-regulation of, 605, 607–609, 607f
 in mammals
 loss of alleles, progressive, 645f
 up-regulation of genes, 644–645, 646f
xol-1 gene/protein, 601–602, 602f
Xp inactivation, 614–616, 615f
Xpr, 653
X signal elements, 601–602, 602f
- Y**
Y chromosome, evolution of, 643f
Yeast. *See also Saccharomyces cerevisiae*
 generation time, 243
 genetic and molecular tools of, 243
 genome size, 242
 heterochromatin boundary function, 255f, 256
 histone acetyltransferases (HATs), 120–121, 121f
 life cycle, 245, 246f
 mating type switching, 245, 247f
 trithorax group (TrxG) proteins, 494t
YEsa1, 120t, 121–122, 121f, 123f, 125–126, 125f,
 127f, 129
yKu, 248, 253, 254f, 257, 259
YY1, 87
- Z**
ZBTB24, 846
ZF-CxxC proteins, 30–32, 31f
Zfp57, 223, 224f, 680, 680f
ZINC FINGER DNA 3' PHOSPHOESTERASE
 (ZDP), 373–374
Zinc-finger nucleases (ZFNs), 726, 727f
ZMET2, 200–201, 200f, 231
Zygote, 688, 689f–690f, 690–691, 701